



CURRICULUM VITAE

Tapan M. Kadia, M.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Leader, AML Section, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Co-Leader, Section of Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center

1515 Holcombe Blvd.

Unit Number: 428

Houston, TX 77030

Room Number: FC4.3058

Phone: 713-563-3534

Fax: 713-563-7746

EDUCATION

Degree-Granting Education

Rutgers University, New Brunswick, NJ, BA, 1998, Bachelor of Arts

Robert Wood Johnson Medical School, Piscataway, NJ, MD, 2001, Doctor of Medicine

Postgraduate Training

Clinical Internship, Baylor College of Medicine Affiliated Hospitals, Houston, TX, 7/2001-6/2002

Clinical Residency, Baylor College of Medicine Affiliated Hospitals, Houston, TX, 7/2002-6/2004

Chief Residency, Baylor College of Medicine Affiliated Hospitals, Houston, TX, 7/2004-6/2005

Clinical Fellowship, Hematology/Oncology, MD Anderson Cancer Center, Houston, TX, 7/2005-6/2008

CREDENTIALS

Board Certification

Internal Medicine, American Board of Internal Medicine, 8/2004

Hematology, American Board of Internal Medicine, 10/2008, Recertification Date: 2028

Medical Oncology, American Board of Internal Medicine, 10/2008

Licensures

Active

Texas State Board of Medical Examiners, M0120, 12/2004-2/2022

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2008-9/2015

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2015-present

Administrative Appointments/Responsibilities

Committee Chair, Division of Cancer Medicine, Leukemia New Patient Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2014-present

Committee Chair, MD Anderson Cancer Center - Board Review in Hematology Oncology, Houston, TX, 9/2019-present

Fellowship Program Associate Director, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center Leukemia Fellowship Program, Houston, TX, 9/2019-present

Committee Vice Chair, Data Safety Monitoring Committee (DSMC) - MDACC, Houston, TX, 1/2020-present

Other Appointments/Responsibilities

Member, EPIC Rollout Committee, Houston, TX, 9/2014-8/2015

Co-Leader, AML Section, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, 9/2019-present

Co-Leader, Section of Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, 9/2019-present

Endowed Positions

N/A

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

Fellowship Steering Committee, Member, Leukemia Department Representative, 1/2010-present

Clinical Research Committee (CRC, SRC), MD Anderson Cancer Center, Member, 7/2010-9/2019

Clinical Affairs Subcommittee, Faculty Senate, MD Anderson Cancer Center, Member, 9/2011-9/2017

Faculty Senate, Member, 9/2011-9/2017

MD Anderson Hematology and Medical Oncology Board Review Steering Committee, Member (Promoted to Co-Chair), 1/2012-9/2019

Credentials Committee, MD Anderson Cancer Center, Member, 9/2013-present

Institutional Committee on Sepsis, Member, 1/2016-present

Utilization Review Committee, Member, 1/2016-present

MD Anderson Physicians Network Multidisciplinary Planning Conferences (MPC), Member, 9/2016-present

PRS Budget & Finance Committee, Elected Member, 3/2017-present

Institutional Goals of Care Committee, Member, 3/2020-present

ICU Utilization Committee, Member, 3/2020-present

HONORS AND AWARDS

Rutgers College Award of Excellence, 1995

Rutgers College Award of Excellence, 1996

Norman Reitman Scholar, 1998

Articulated BA/MD Program, 2000

Dean's List, Rutgers College, 2000

Member, Golden Key National Honor Society, 2000

Member, Phi Beta Kappa Honor Society, 2000

Member, Phi Eta Sigma Honor Society, 2000

Recipient of The Waksman Fellowship for Undergraduate Research, 2000

UMDNJ Research Fellowship, 2000

Chief Residency, Internal Medicine, Baylor College of Medicine, 2004

AACR/ASCO Workshop Methods in Clinical Cancer Research Vail, 2006

AACR/ASCO Workshop Molecular Biology in Clinical Oncology Aspen, 2006

FOREM Lymphoma Research Award, Runner up, 2006

Recipient of The Paul Calabresi Clinical Oncology Award-K12 Grant, 2006

Recipient of The Paul Calabresi Clinical Oncology Award-K12 Grant, 2008

RESEARCH

Grants and Contracts

Funded

Co-Principal Investigator, 0.12 months, A Phase IIa Study of BL-8040 in Combination with Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma, 5-P50-CA171963-05, NIH/NCI, PI - Geoffrey Uy, 7/1/2017-6/30/2023, \$31,250 (\$10,000/year)

Principal Investigator, A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies, 2018-0484, M.D. Anderson Cancer Center, 9/26/2018-present, \$571,120

Principal Investigator, 5%, Pre-Clinical Efficacy of CDK7 inhibitor-based combinations against AML including Post-Myeloproliferative Neoplasm (post-MPN) sAML Cells, IRG, 1/1/2020-12/31/2022, \$75,000 (\$37,500/year)

Pending

Co-Investigator, 0.6 months, SPORE in Leukemia Project 2: Anti-PR1 for Myeloid Leukemia, P50CA100632, NIH/NCI, PI - Marina Konopleva, 9/1/2018-8/31/2023, \$172,616

Other

N/A

Completed

N/A

Not Funded

N/A

Protocols

Funded

Co-Investigator with Mentor, Phase I Study of Suberoylanilide Hydroxamic Acid in Combination with Idarubicin for Patients with Relapsed Leukemia, CTEP study 2005-0031/UO1 CA062461, PI - Razelle Kurzock, 2005-2010, NIH/NCI CTEP

Principal Investigator, Phase II study of combination of thymoglobulin, cyclosporine, methylprednisone, and GCSF in patients with newly diagnosed aplastic anemia or with hypoplastic or low/intermediate - 1 risk myelodysplastic syndrome, 2005-0115, 2005-2011, Genzyme

Study Chairman, A Phase II Study of Bafetinib(INNO-406) as Treatment for Patients with Relapsed or Refractory B- Cell Chronic Lymphocytic Leukemia (B-CLL), 2010-0175, 2010-2013

Principal Investigator, A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients with Relapsed/ Refractory Lymphoid Malignancies, 2009-0717, 2010-2015, \$118,900 (\$23,975/year), GlaxoSmithKline

Study Chairman, Compassionate Use Single Patient Study for treatment with Marqibo + Rituxan in a Patient with ALL, CIND12-0075, 2012-2013, Talon Therapeutics

Study Chairman, Phase II Study of Lenalidomide Maintenance in Patients with High Risk AML in Remission., 2014-0116, 2014-present, \$251,700, Celgene

Study Chairman, A Phase 1 Study of KB003 in Subjects with Previously Treated Chronic Myelomonocytic Leukemia (CMML), 2015-0673, 2015-2016, \$122,950, Kalo Bios

Study Chairman, A Phase IB, Open-label Pilot Study Designed to Evaluate the Efficacy and Safety of BL-8040 followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects with Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS), 2015-0408, 2015-2019, \$204,529 (\$45,451/year), BiolineRX

Study Chairman, PD-1 Inhibition with Nivolumab for the Treatment of Patients with Acute Myeloid Leukemia in Remission at High Risk for Relapse, 2015-0213, 2015-present, \$256,000 (\$28,444/year), Bristol Myers Squibb

Study Chairman, Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase I.V. in Patients with Relapsed or Refractory Hematologic Malignancies, 2015-0807, 2016-2017, Jazz Pharmaceuticals

Study Chairman, Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous Infusion in Patients with RELapsed or Refractory T-acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma, 2016-0789, 2017-2018, \$299,531, Sanofi US Services Inc.

Study Chairman, A Phase IIa Study of BL-8040 in Combination with Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma, 2016-1101, 2017-present, NIH, Washington University, BiolineRX, Ltd

Principal Investigator, Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory Leukemias, 2016-0772, 2017-present, \$469,937 (\$313,291/year), Pfizer

Principal Investigator, Phase II Study of CPX-351 in Combination with Venetoclax in Patients with Acute Myeloid Leukemia (AML), 2017-1055, 2017-present, \$1,150,000, Jazz Pharmaceuticals

Principal Investigator, A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia, 2017-0776, 2018, \$562,973 (\$562,973/year), Amgen

Principal Investigator, A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies, 2018-0484, 2018-present, \$571,120, Amgen

Principal Investigator, Phase I Trial to Evaluate the Safety of CK0801 in Treatment of Bone Marrow Failure Syndromes, 2018-0010, 2018-present, \$572,186, Cellenkos

Principal Investigator, Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation with Cladribine Plus LDAC Alternating with 5-Azacitidine in Patients with Untreated AML, 2018-0020, 2018-present, AbbVie

Principal Investigator, Strategic Alliance: 2009-1002 a Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia or Myelodysplastic Syndromes, 2009-1002, 2019-2021, \$954,375, Cyclacel

Principal Investigator, Ibrutinib + Venetoclax in T-PLL, 2019-1069, 2019-present, \$40,626, AbbVie

Principal Investigator, Ph1 JNJ-67571244 (CD33-CD3) in AML or MDS, 2019-0950, 2019-present, \$1,221,250, Janssen Research and Development LLC

Principal Investigator, Ph1b Itacitinib + Alemtuzumab in T-PLL, 2019-0054, 2019-present, \$266,648, Incyte Corporation

Principal Investigator, Ph3 Randomized DFP-10917 V. Non-intensive OR Intensive Reinduction for AML in 2nd or 3rd Salvage, 2019-0357, 2019-present, \$852,382, Delta-Fly Pharma, Inc.

Principal Investigator, PhII AZA + Venetoclax as Maintenance for HR-AML, 2019-0226, 2019-present, \$1,625,000, Genentech, Inc.

Principal Investigator, Fludarabine, Cytarabine, and Pegcristantaspase in R/R Leukemias, 2020-0434, 2020-present, \$1,242,000, Jazz Pharmaceuticals

Principal Investigator, Ph1 GFH009 in R/R Hematologic Malignancies, 2020-0689, 2020-present, GenFleet

Principal Investigator, Ph1 Tegavivint (BC-2059) in R/R AML, 2020-0616, 2020-present, Iterion Therapeutics

Principal Investigator, Ph1b VEN + AMG176, 2020-0001, 2020-present, AbbVie

Principal Investigator, Ph1b/2 APG-115 Alone or APG-115 + Aza in R/R AML, 2020-0422, 2020-present, Ascentage Pharma Group Inc.

Principal Investigator, PhIIA APG-115 +/- APG-2575 in R/R T-PLL, 2020-0001, 2020-present, Ascentage

Principal Investigator, PUL-042/Placebo in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2, 2020-0407, 2020-present (\$278,170/year), Pulmotect, Inc.

Principal Investigator, PUL-042/Placebo in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection, 2020-0405, 2020-present, \$148,750, Pulmotect, Inc.

Unfunded

Study Chairman, Phase II Pilot Of Study Of Alemtuzumab In Patients With Low or INT - 1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T - Cell Large Granular Lymphocytic Leukemia, 2010-0187, 2010-2016, Sanofi

Study Chairman, Phase II Study Of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine In Patients With Untreated AML Or High-Risk, 2011-0987, 2011-present

Study Chairman, Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisone, and GCSF (Filgrastim or Pegfilgrastim) in Patients with Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS), 2012-0334, 2012-present

Study Chairman, PHASE II STUDY OF CLADRIBINE PLUS IDARUBICIN PLUS CYTARABINE (ARAC) IN PATIENTS WITH AML, HR MDS, OR MYELOID BLAST PHASE OF CML., 2012-0648, 2014-present

Study Chairman, A Retrospective Review and Prospective Database of Patients with T-cell Prolymphocytic Leukemia (T-PLL), PA16-0709, 2016-present

Study Chairman, Clinical Outcomes in Adult Patients with Aplastic Anemia: A single Institution Experience, PA17-0265, 2017-present

Principal Investigator, Evaluation of the prognostic impact of smoking status at diagnosis in patients with acute myeloid leukemia, PA18-0858, 2018-present

Principal Investigator, Phase I Study of C188-9 in Patients with Relapsed and Refractory Leukemias, 2018-0436, 2018-present, Tvardi

Principal Investigator, Viability and Function of T-lymphocytes in Patients with Leukemias and Bone Marrow Failure Disorders, PA18-0591, 2018-present

Patents and Technology Licenses

Patents

Glaxosmithkline Intellectual Propert (No. 2) Limited, Manuel Carlos Alves-Aivado, Gautam Borthakur, Tapan M. Kadia, Hagop M. Kantarjian, Sylvie Laquerre. Methods for Treating Cancer, Treating RAS-Mutated AML, United States, US20130217710A1, 11/4/2011, Issued

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

N/A

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Mendez J, **Kadia TM**, Somayazula RK, El-Badawi KI, Cowen DS. Differential coupling of serotonin 5-HT1A and 5-HT1B receptors to activation of ERK2 and inhibition of adenyl cyclase in transfected CHO cells. *J Neurochem* 73(1):162-8, 7/1999. PMID: 10386967.
2. Kadia TM, Garcia-Manero G. Role of epigenetic therapy in myelodysplastic syndrome. *Expert Rev Hematol* 1(2):161-174, 12/2008. PMCID: PMC3833719.
3. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. *Blood* 113(9):1892-8, 2/2009. e-Pub 12/2008. PMCID: PMC2651008.
4. Walker JG, Kadia T, Brown L, Juneja HS, de Groot JF. Dapsone induced methemoglobinemia in a patient with glioblastoma. *J Neurooncol* 94(1):149-52, 8/2009. e-Pub 2/2009. PMCID: PMC4438990.
5. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. *J Clin Oncol* 28(3):392-7, 1/2010. e-Pub 12/2009. PMCID: PMC2815701.
6. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. *Br J Haematol* 150(1):72-82, 7/2010. e-Pub 4/2010. PMCID: PMC4124904.
7. Parikh SA, Kadia T, Jabbour E. Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. *Clin Lymphoma Myeloma Leuk* 10(4):301-2, 8/2010. PMID: 20709669.
8. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, Garcia-Manero G. The Combination of a Histone Deacetylase Inhibitor with the BH3-

- Mimetic GX15-070 has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy. *Clin Cancer Res* 16(15):3923-32, 8/2010. e-Pub 6/2010. PMID: PMC4113507.
9. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. *Autophagy* 6(7):976-8, 10/2010. e-Pub 10/2010. PMID: 20729640.
 10. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. *Blood* 116(22):4422-9, 11/2010. e-Pub 7/2010. PMID: PMC4081299.
 11. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. *J Clin Oncol* 29(18):2507-13, 6/2011. e-Pub 5/2011. PMID: PMC4874214.
 12. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. *J Clin Oncol* 29(23):3173-8, 8/2011. e-Pub 7/2011. PMID: PMC4874216.
 13. Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. *Semin Oncol* 38(5):682-92, 10/2011. PMID: PMC4098768.
 14. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. *Am J Hematol* 87(1):127-9, 1/2012. e-Pub 11/2011. PMID: PMC4085038.
 15. Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur G. Hypocellular acute myeloid leukemia in adults: clinical outcome analysis of 123 patients. *Haematologica* 97(2):235-40, 2/2012. e-Pub 11/2011. PMID: PMC3269483.
 16. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. *Blood* 119(9):1981-7, 3/2012. e-Pub 1/2012. PMID: PMC3311242.
 17. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. *Br J Haematol* 157(3):312-20, 5/2012. e-Pub 2/2012. PMID: PMC3924750.
 18. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. *Cancer* 118(10):2665-73, 5/2012. e-Pub 10/2011. PMID: PMC4060157.
 19. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthakur G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. *Invest New Drugs* 30(3):1107-15, 6/2012. e-Pub 4/2011. PMID: PMC4205950.
 20. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. *J Clin Oncol* 30(18):2204-10, 6/2012. e-Pub 5/2012. PMID: PMC4879705.

21. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. *Clin Lymphoma Myeloma Leuk* 12(3):197-200, 6/2012. PMID: PMC4050633.
22. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. *Cancer* 118(14):3556-64, 7/2012. e-Pub 12/2011. PMID: PMC4984525.
23. Sharp H, Grosshans D, Kadia T, Dabaja BS. Cutaneous graft-versus-host disease after proton-based craniospinal irradiation for recurrent Philadelphia-positive acute lymphoblastic leukaemia. *BMJ Case Rep* 2012, 7/2012. e-Pub 7/2012. PMID: PMC3417036.
24. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. *Haematologica* 97(8):1242-5, 8/2012. e-Pub 4/2012. PMID: PMC3409823.
25. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. *Blood* 120(6):1202-9, 8/2012. e-Pub 6/2012. PMID: PMC4081158.
26. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 12(4):244-51, 8/2012. e-Pub 4/2012. PMID: PMC3859239.
27. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. *Cancer* 118(18):4471-7, 9/2012. e-Pub 1/2012. PMID: PMC3907176.
28. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. *Cancer* 118(18):4462-70, 9/2012. e-Pub 1/2012. PMID: PMC3913560.
29. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. *Cancer* 118(22):5550-9, 11/2012. e-Pub 5/2012. PMID: PMC3416961.
30. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. *Cancer* 118(23):5819-22, 12/2012. e-Pub 5/2012. PMID: PMC4184417.
31. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. *Am J Hematol* 88(1):56-9, 1/2013. e-Pub 10/2012. PMID: PMC4085099.
32. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 study of anti-CD33 immunotoxin HUM-195/rGEL in patients with advanced myeloid malignancies. *Haematologica* 98(2):217-21, 2/2013. e-Pub 8/2012. PMID: PMC3561428.
33. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giral S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating

- agents in patients with myelodysplastic syndrome: a retrospective case-control study. *Am J Hematol* 88(3):198-200, 3/2013. e-Pub 1/2013. PMID: PMC4085133.
34. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. *Leukemia* 27(4):836-42, 4/2013. e-Pub 11/2012. PMID: PMC4181539.
 35. Jain P, Sargent RL, Konoplev SN, Benjamini O, Kantarjian H, Kadia T. Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase. *Am J Hematol* 88(5):433-4, 5/2013. e-Pub 3/2013. PMID: 23460270.
 36. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. *Am J Hematol* 88(5):365-9, 5/2013. e-Pub 3/2013. PMID: PMC4089101.
 37. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood* 121(23):4655-62, 6/2013. e-Pub 4/2013. PMID: PMC3674666.
 38. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 13 Suppl 2:S276-81, 9/2013. e-Pub 8/2013. PMID: PMC4101888.
 39. Jain P, Benjamini O, Pei L, Caraway NP, Landon G, Kim S, Shivaprasad S, Woodman K, O'Brien S, Ferrajoli A, Kadia T, Estrov Z. Central nervous system Richter's transformation and parvovirus B19 infection. *Leuk Lymphoma* 54(9):2070-2, 9/2013. e-Pub 3/2013. PMID: PMC4114215.
 40. Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. *Clin Lymphoma Myeloma Leuk* 13 Suppl 2:S289-94, 9/2013. e-Pub 8/2013. PMID: PMC4120258.
 41. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. *Am J Hematol* 88(10):831-7, 10/2013. e-Pub 7/2013. PMID: PMC3923606.
 42. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. *Clin Lymphoma Myeloma Leuk* 13(5):592-6, 10/2013. e-Pub 6/2013. PMID: PMC4120256.
 43. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia. *Am J Hematol* 88(11):961-6, 11/2013. e-Pub 9/2013. PMID: PMC4110914.
 44. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. *Leuk Res* 37(11):1440-4, 11/2013. e-Pub 7/2013. PMID: PMC4232180.
 45. Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with

- myelodysplastic syndrome and chronic myelomonocytic leukemia post clofarabine failure. *Ther Adv Hematol* 5(2):29-34, 4/2014. PMID: PMC3949300.
46. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. *Clin Cancer Res* 20(8):2226-35, 4/2014. e-Pub 2/2014. PMID: PMC3989412.
 47. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. *Clin Lymphoma Myeloma Leuk* 14(2):163-71, 4/2014. e-Pub 1/2014. PMID: PMC4167660.
 48. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. *Leukemia* 28(4):973-5, 4/2014. e-Pub 10/2013. PMID: 24157581.
 49. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. *Clin Lymphoma Myeloma Leuk* 14(2):155-162.e1, 4/2014. e-Pub 12/2013. PMID: PMC3959284.
 50. Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. *Am J Hematol* 89(5):509-16, 5/2014. e-Pub 2/2014. PMID: PMC4221257.
 51. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. *Clin Lymphoma Myeloma Leuk* 14(3):223-30, 6/2014. e-Pub 11/2013. PMID: PMC4096861.
 52. Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M. Case series of AML patients receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. *Leuk Lymphoma* 55(6):1431-4, 6/2014. e-Pub 11/2013. PMID: PMC4105975.
 53. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. *Leuk Lymphoma* 55(6):1337-44, 6/2014. e-Pub 10/2013. PMID: PMC4143910.
 54. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. *Clin Lymphoma Myeloma Leuk* 14(3):231-8, 6/2014. e-Pub 12/2013. PMID: PMC4182922.
 55. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. *Leuk Lymphoma* 55(8):1925-9, 8/2014. e-Pub 2/2014. PMID: PMC4139917.
 56. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. *Leuk Res* 38(9):1126-9, 9/2014. e-Pub 7/2014. PMID: PMC4157096.
 57. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic

- Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 14(5):401-10, 10/2014. e-Pub 5/2014. PMID: PMC4167474.
58. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. *Am J Hematol* 89(10):964-8, 10/2014. e-Pub 7/2014. PMID: PMC4431614.
 59. Willis L, Rexwinkle A, Bryan J, Kadia TM. Recent Developments in Drug Therapy for Aplastic Anemia. *Ann Pharmacother* 48(11):1469-1478, 11/2014. e-Pub 9/2014. PMID: 25184310.
 60. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). *Cancer* 120(23):3660-8, 12/2014. e-Pub 7/2014. PMID: PMC4239168.
 61. Dinardo CD, Daver N, Jabbour E, **Kadia T**, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian H, and Garcia-Manero G. Sequential azacytidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm phase I/II study. *The Lancet Hematology*, 12/2014.
 62. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacytidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. *Lancet Haematol* 2(1):e12-20, 1/2015. e-Pub 12/2014. PMID: PMC4936479.
 63. **Kadia TM**, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, and Kantarjian H. Final Results of the Phase II Trial of Clofarabine and Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. *Cancer*, 2/2015.
 64. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II Study of Methotrexate, Vincristine, Pegylated-Asparaginase, and Dexamethasone (MOpAD) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. *Am J Hematol* 90(2):120-4, 2/2015. e-Pub 11/2014. PMID: PMC4447180.
 65. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes. *Leuk Lymphoma* 56(2):1-21, 2/2015. e-Pub 7/2014. PMID: PMC4297591.
 66. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 15(3):171-6, 3/2015. e-Pub 9/2014. PMID: PMC4344906.
 67. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. *Br J Haematol* 168(5):646-53, 3/2015. e-Pub 10/2014. PMID: PMC4323735.
 68. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. *Cancer* 121(6):876-82, 3/2015. e-Pub 11/2014. PMID: PMC4378905.

69. Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a cd22 monoclonal antibody. *Am J Hematol* 90(3):193-6, 3/2015. e-Pub 1/2015. PMID: 25407953.
70. Kadia TM, Ravandi F, O'Brien S, Cortes J, Kantarjian HM. Progress in Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 15(3):139-51, 3/2015. e-Pub 9/2014. PMID: PMC4344862.
71. Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. *Leuk Lymphoma* 56(4):1-8, 4/2015. e-Pub 8/2014. PMID: PMC4326620.
72. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *Am J Hematol* 90(4):276-81, 4/2015. e-Pub 3/2015. PMID: PMC4376596.
73. **Kadia TM**, Ravandi F, Cortes J, Kantarjian H. Towards Individualized Therapy in Acute Myeloid Leukemia. *JAMA Oncol*. Published online April 30, 2015. doi:10.1001/jamaoncol.2015.0617, 4/2015.
74. Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. *Haematologica* 100(5):653-61, 5/2015. e-Pub 2/2015. PMID: PMC4420214.
75. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. *Leuk Lymphoma* 56(5):1-12, 5/2015. e-Pub 11/2014. PMID: PMC4417657.
76. Kadia TM, Thomas XG, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H. Decitabine improves outcomes in older patients with acute myeloid leukemia (AML) and higher blast counts. *Am J Hematol* 90(7):E139-41, 7/2015. e-Pub 5/2015. PMID: PMC4478207.
77. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. *Cancer* 121(14):2375-82, 7/2015. e-Pub 3/2015. PMID: 25809968.
78. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. *Haematologica* 100(7):927-34, 7/2015. e-Pub 2/2015. PMID: PMC4486227.
79. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark Brandt, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. *Am J Hematol* 90(8):732-6, 8/2015. e-Pub 5/2015. PMID: PMC4612499.
80. Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. *Invest New Drugs* 33(4):870-80, 8/2015. e-Pub 5/2015. PMID: 25933833.
81. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the

- Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. *Br J Haematol* 170(4):590-3, 8/2015. e-Pub 2/2015. PMID: PMC4977576.
82. Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. *Haematologica* 100(8):1058-63, 8/2015. e-Pub 6/2015. PMID: PMC5004422.
 83. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. *Am J Hematol* 90(9):769-73, 9/2015. e-Pub 7/2015. PMID: PMC4546505.
 84. Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. *JAMA Oncol* 1(6):820-8, 9/2015. PMID: 26181162.
 85. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannon Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. *Lancet Oncol* 16(15):1547-55, 11/2015. e-Pub 9/2015. PMID: PMC4816046.
 86. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. *Am J Hematol* 90(11):1065-70, 11/2015. e-Pub 9/2015. PMID: PMC4618182.
 87. Ravandi F, Pigneux A, DeAngelo DJ, Raffoux E, Delaunay J, Thomas X, Kadia T, Kantarjian H, Scheuenpflug J, Zhao C, Guo W, Smith BD. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. *Blood Cancer J* 5:e375, 12/2015. e-Pub 12/2015. PMID: PMC4735070.
 88. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannon Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. *Leuk Res* 39(12):1367-74, 12/2015. e-Pub 10/2015. PMID: PMC4822515.
 89. Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine. *Biomed Res Int* 2015:497597, 2015. e-Pub 1/2015. PMID: PMC4310492.
 90. Kadia TM, Ravandi F. Alemtuzumab in T-cell large granular lymphocyte leukaemia. *Lancet Haematol* 3(1):e4-5, 1/2016. e-Pub 12/2015. PMID: 26765647.
 91. Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. *Leukemia* 30(2):268-73, 2/2016. e-Pub 9/2015. PMID: PMC4790089.
 92. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. *Br J Haematol* 172(3):392-400, 2/2016. e-Pub 10/2015. PMID: PMC4826052.

93. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. *Oncotarget* 7(12):14172-87, 3/2016. e-Pub 2/2016. PMID: PMC4924706.
94. Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. *Clin Lymphoma Myeloma Leuk* 16(3):152-62, 3/2016. e-Pub 12/2015. PMID: PMC4769134.
95. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. *Clin Lymphoma Myeloma Leuk* 16(3):163-168.e2, 3/2016. e-Pub 11/2015. PMID: PMC4804759.
96. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Blood* 127(10):1269-75, 3/2016. e-Pub 1/2016. PMID: PMC4786836.
97. Kadia TM. Release the hounds: virotherapy with immunotherapy. *Blood* 127(11):1381-3, 3/2016. PMID: PMC4797017.
98. Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Noguera Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. *Br J Haematol* 173(1):114-26, 4/2016. e-Pub 2/2016. PMID: PMC4809772.
99. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. *Blood* 127(15):1863-9, 4/2016. e-Pub 1/2016. PMID: PMC4915808.
100. Kadia TM, Ravandi F, Cortes J, Kantarjian H. New drugs in acute myeloid leukemia. *Ann Oncol* 27(5):770-8, 5/2016. e-Pub 1/2016. PMID: PMC4843183.
101. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. *Cancer* 122(12):1871-9, 6/2016. e-Pub 3/2016. PMID: 26990290.
102. Wang W, Tang G, Kadia T, Lu X, Li Y, Huang L, Montenegro-Garreaud X, Miranda RN, Wang SA. Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11;q11)/BCR-FGFR1 Rearrangement. *J Natl Compr Canc Netw* 14(6):708-11, 6/2016. PMID: 27283163.
103. Kadia TM. Personalized treatment for patients with myelofibrosis. *Clin Adv Hematol Oncol* 14(6):400-3, 6/2016. PMID: 27379807.
104. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. *Am J Hematol* 91(4):385-9, 6/2016. e-Pub 2/2016. PMID: 26800008.
105. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, DiNardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. *Cancer*. e-Pub 7/2016. PMID: PMC5269552.

106. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. *Am J Hematol* 91(8):819-23, 8/2016. e-Pub 6/2016. PMCID: PMC5558853.
107. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. *Cancer* 122(16):2505-11, 8/2016. e-Pub 5/2016. PMID: 27182988.
108. Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. *Clin Case Rep* 4(8):765-7, 8/2016. e-Pub 7/2016. PMCID: PMC4974424.
109. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Levenson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. *Cancer Discov* 6(10):1106-1117, 10/2016. e-Pub 8/2016. PMCID: PMC5436271.
110. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. *Cancer* 122(21):3336-3343, 11/2016. e-Pub 8/2016. PMCID: PMC5073019.
111. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. *Clin Lymphoma Myeloma Leuk* 16(11):616-624, 11/2016. e-Pub 8/2016. PMCID: PMC5408349.
112. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. *Cancer* 122(23):3650-3656, 12/2016. e-Pub 8/2016. PMCID: PMC5321539.
113. Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. *Am J Hematol* 91(12):1221-1226, 12/2016. e-Pub 8/2016. PMCID: PMC5118152.
114. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. *Cancer* 122(24):3812-3820, 12/2016. e-Pub 8/2016. PMCID: PMC5321530.
115. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. *Bone Marrow Transplant* 52(1):28-33, 1/2017. e-Pub 9/2016. PMCID: PMC5849052.
116. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with

- relapsed/refractory B-cell acute lymphoblastic leukemia. *Cancer* 123(2):294-302, 1/2017. e-Pub 9/2016. PMID: PMC5321541.
117. Jain P, Nagarajan P, Prayag P, Benton CB, Kadia T, Groisberg R, Kontoyiannis DP, Mulanovich VE, Pemmaraju N. Mixed angioinvasive *Exserohilum* and *Scedosporium* infection in a patient with AML. *Am J Hematol* 92(1):119-120, 1/2017. e-Pub 7/2016. PMID: PMC5884637.
 118. Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. *Expert Rev Hematol* 10(1):1-8, 1/2017. e-Pub 12/2016. PMID: PMC5578611.
 119. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. *Leukemia* 31(2):318-324, 2/2017. e-Pub 10/2016. PMID: 27795561.
 120. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. *Am J Hematol* 92(2):155-160, 2/2017. PMID: PMC5338569.
 121. Tamamyian G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. *Crit Rev Oncol Hematol* 110:20-34, 2/2017. e-Pub 12/2016. PMID: PMC5410376.
 122. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. *Cancer* 123(3):426-435, 2/2017. e-Pub 9/2016. PMID: PMC5258784.
 123. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduikie R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. *Cancer* 123(4):629-637, 2/2017. e-Pub 10/2016. PMID: 27741352.
 124. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. *Cancer* 123(3):459-467, 2/2017. e-Pub 10/2016. PMID: PMC5321542.
 125. Dinardo CD, Luskin MR, Carroll M, Smith C, Harrison J, Pierce S, Kornblau S, Konopleva M, Kadia T, Kantarjian H, Wertheim GB, Master SR. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. *Am J Hematol* 92(2):E14-E15, 2/2017. PMID: PMC5915352.
 126. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. *Oncotarget* 8(13):22104-22112, 3/2017. e-Pub 9/2016. PMID: PMC5400650.
 127. Saenz DT, Fiskus W, Manshoury T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. *Leukemia* 31(3):678-687, 3/2017. e-Pub 9/2016. PMID: PMC5345582.
 128. Khan M, Mansoor AE, Kadia TM. Future prospects of therapeutic clinical trials in acute myeloid leukemia. *Future Oncol* 13(6):523-535, 3/2017. e-Pub 10/2016. PMID: PMC5296715.

129. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. *Blood* 129(10):1275-1283, 3/2017. e-Pub 12/2016. PMID: PMC5413297.
130. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. *Am J Hematol* 92(3):238-243, 3/2017. e-Pub 2/2017. PMID: PMC5495018.
131. Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. *Am J Hematol* 92(3):279-285, 3/2017. e-Pub 2/2017. PMID: PMC5851443.
132. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. *Am J Hematol* 92(4):351-358, 4/2017. e-Pub 2/2017. PMID: PMC5439522.
133. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. *Blood* 129(18):2584-2587, 5/2017. e-Pub 2/2017. PMID: PMC5418636.
134. Boddu PC, Kadia TM. Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review. *Expert Rev Hematol* 10(5):1-16, 5/2017. e-Pub 4/2017. PMID: 28452257.
135. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. *Leukemia* 31(7):1659, 7/2017. e-Pub 3/2017. PMID: 28338082.
136. Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. *Am J Hematol* 92(7):674-682, 7/2017. e-Pub 6/2017. PMID: PMC5580683.
137. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). *Ann Oncol* 28(7):1554-1559, 7/2017. e-Pub 4/2017. PMID: PMC5834082.
138. Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. *Int J Mol Sci* 18(8), 7/2017. e-Pub 7/2017. PMID: PMC5578010.
139. Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with

- hypomethylating agents. *Am J Hematol* 92(7):599-606, 7/2017. e-Pub 5/2017. PMID: PMC5553721.
140. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, **Kadia TM**. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. *Blood Adv* 1(17):1312-1323, 7/2017. e-Pub 7/2017. PMID: PMC5727976.
 141. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. *Cancer* 123(16):3050-3060, 8/2017. e-Pub 4/2017. PMID: PMC5544569.
 142. Boddu P, Kantarjian H, Borthakur G, **Kadia T**, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. *Blood Adv* 1(19):1546-1550, 8/2017. e-Pub 8/2017. PMID: PMC5728474.
 143. Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. *Leukemia*. e-Pub 9/2017. PMID: 28919634.
 144. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. *Am J Hematol* 92(9):924-928, 9/2017. e-Pub 7/2017. PMID: 28556489.
 145. Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. *Am J Hematol* 92(9):845-850, 9/2017. e-Pub 6/2017. PMID: 28494506.
 146. Saenz DT, Fiskus W, Qian Y, Manshour T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. *Leukemia* 31(9):1951-1961, 9/2017. e-Pub 2/2017. PMID: PMC5537055.
 147. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. *Blood* 130(13):1514-1522, 9/2017. e-Pub 8/2017. PMID: PMC5620419.
 148. Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens. *Am J Hematol* 92(10):E595-E597, 10/2017. e-Pub 7/2017. PMID: PMC5689471.
 149. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. *Cancer* 123(19):3717-3724, 10/2017. e-Pub 6/2017. PMID: PMC5689475.
 150. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Noguera-González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in

- combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. *Haematologica* 102(10):1709-1717, 10/2017. e-Pub 7/2017. PMID: PMC5622855.
151. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. *Cancer* 123(22):4430-4439, 11/2017. e-Pub 7/2017. PMID: 28708931.
 152. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia negative metaphases during CML treatment. *Blood* 130(19):2084-2091, 11/2017. e-Pub 8/2017. PMID: PMC5680612.
 153. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Noguera Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. *Cancer* 123(22):4391-4402, 11/2017. e-Pub 7/2017. PMID: PMC5673547.
 154. Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. *Am J Hematol* 92(12):1295-1302, 12/2017. e-Pub 9/2017. PMID: 28850699.
 155. Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. *Cancer* 123(24):4851-4859, 12/2017. e-Pub 8/2017. PMID: 28841236.
 156. Boddu P, Yin CC, Kanagal-Shamanna R, Tang G, Thakral B, Kadia T, Konopleva M, Jabbour E, Jain N. An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. *Case Rep Hematol* 2017:2413587, 2017. e-Pub 9/2017. PMID: PMC5624137.
 157. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. *Am J Hematol* 93(1):91-99, 1/2018. e-Pub 11/2017. PMID: 29047158.
 158. Alhurajji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, **Kadia T**, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. *Am J Hematol* 93(1):84-90, 1/2018. e-Pub 11/2017. PMID: 29027261.
 159. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Noguera-Gonzalez G, Jabbour E, Bose P, **Kadia T**, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A Phase II Trial of Ruxolitinib in Combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. *Am J Hematol* 93(2):277-285, 2/2018. e-Pub 11/2017. PMID: 29134664.
 160. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Noguera GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, **Kadia T**, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or

- myelodysplastic/myeloproliferative neoplasms. *Oncotarget* 9(11):9714-9727, 2/2018. e-Pub 1/2018. PMID: PMC5839396.
161. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. *Lancet Oncol* 19(2):240-248, 2/2018. e-Pub 1/2018. PMID: 29352703.
 162. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, **Kadia T**, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. *JAMA Oncol* 4(2):230-234, 2/2018. e-Pub 8/2017. PMID: PMC5838597.
 163. DiNardo CD, Rausch CR, Benton C, **Kadia T**, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies. *Am J Hematol* 93(3):401-407, 3/2018. e-Pub 12/2017. PMID: 29218851.
 164. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, **Kadia TM**, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma* 59(4):1-8, 4/2018. e-Pub 7/2017. PMID: PMC5773400.
 165. Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, **Kadia TM**, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. *Leukemia*. e-Pub 4/2018. PMID: PMC6202273.
 166. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, **Kadia T**, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. *Lancet Haematol* 5(4):e136-e146, 4/2018. e-Pub 3/2018. PMID: 29550383.
 167. Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver N, Pemmaraju N, Pierce S, Cortes J, **Kadia TM**. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. *Leuk Lymphoma* 59(4):1-4, 4/2018. e-Pub 8/2017. PMID: 28838278.
 168. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, **Kadia T**, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. *Int J Hematol* 107(6):689-695, 6/2018. e-Pub 2/2018. PMID: 29464484.
 169. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, **Kadia T**, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. *J Clin Oncol* 36(18):1788-1797, 6/2018. e-Pub 4/2018. PMID: PMC6008108.
 170. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, **Kadia T**, Ravandi F, Jain N, Alhurajji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. *Leuk Lymphoma* 59(6):1-11, 6/2018. e-Pub 10/2017. PMID: PMC6120342.

171. Boddu P, Oviedo SP, Rausch CR, Yam C, Daver N, Kantarjian H, **Kadia TM**. PET-CT in AML-related hemophagocytic lymphohistiocytosis. *Leuk Lymphoma* 59(6):1-4, 6/2018. e-Pub 9/2017. PMID: 28958191.
172. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, **Kadia TM**, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. *Cancer* 124(12):2534-2540, 6/2018. e-Pub 4/2018. PMID: 29645075.
173. Assi R, Kantarjian HM, **Kadia TM**, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. *Cancer* 124(13):2758-2765, 7/2018. e-Pub 4/2018. PMID: 29660836.
174. **Kadia TM**, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. *Lancet Haematol* 5(9):e411-e421, 9/2018. e-Pub 8/2018. PMID: 30115541.
175. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, **Kadia T**. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. *Leuk Lymphoma* 59(9):2238-2241, 9/2018. e-Pub 1/2018. PMID: 29338567.
176. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, **Kadia T**, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. *Am J Hematol* 93(9):1136-1141, 9/2018. e-Pub 8/2018. PMID: 30028037.
177. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, **Kadia TM**, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. *Blood* 132(16):1664-1674, 10/2018. e-Pub 9/2018. PMID: PMC6265645.
178. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, **Kadia T**, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. *Cancer* 124(20):4044-4055, 10/2018. e-Pub 10/2018. PMID: 30307611.
179. Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, **Kadia TM**, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. *Am J Hematol* 93(10):1245-1253, 10/2018. e-Pub 9/2018. PMID: 30051599.
180. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, **Kadia T**, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. *Cancer Med* 7(11):5457-5469, 11/2018. e-Pub 10/2018. PMID: PMC6246941.
181. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, DiNardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, **Kadia TM**. Addition of eltrombopag to immunosuppressive therapy in patients with newly

- diagnosed aplastic anemia. *Cancer* 124(21):4192-4201, 11/2018. e-Pub 10/2018. PMID: 30307606.
182. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, **Kadia T**, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. *Am J Hematol* 93(11):1376-1383, 11/2018. e-Pub 9/2018. PMID: 30117185.
 183. Abaza Y, Cortes J, Ravandi F, **Kadia T**, Garcia-Manero G, Pemmaraju N, Shetty A, Pierce S, Qiao W, Kantarjian HM, Borthakur G. Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. *Am J Hematol* 93(11):E357-E360, 11/2018. e-Pub 9/2018. PMID: 30074261.
 184. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, **Kadia TM**, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. *Leukemia* 32(11):2388-2398, 11/2018. e-Pub 4/2018. PMCID: PMC6192870.
 185. Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, **Kadia T**, Brandt M, Maduik R, Kantarjian H, Borthakur G. Response kinetics and factors predicting survival in core-binding factor leukemia. *Leukemia* 32(12):2698-2701, 12/2018. e-Pub 6/2018. PMID: 29884905.
 186. Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, **Kadia T**, Jorgensen J, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. *Exp Hematol Oncol* 7:26, 2018. e-Pub 10/2018. PMCID: PMC6174068.
 187. Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? *Blood Cancer J* 9(2):7, 1/2019. e-Pub 1/2019. PMCID: PMC6335405.
 188. Klepin HD, Estey E, Kadia T. More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. *Am Soc Clin Oncol Educ Book* 39:421-432, 1/2019. e-Pub 5/2019. PMID: 31099627.
 189. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Noguera-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. *Leuk Lymphoma* 60(1):1-12, 1/2019. e-Pub 5/2018. PMCID: PMC6226369.
 190. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. *Blood Cancer J* 9(2):4, 1/2019. e-Pub 1/2019. PMCID: PMC6333829.
 191. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. *Lancet Haematol* 6(1):e29-e37, 1/2019. e-Pub 12/2018. PMCID: PMC6563344.
 192. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. *J Hematol Oncol* 12(1):1, 1/2019. e-Pub 1/2019. PMCID: PMC6318861.

193. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. *Cold Spring Harb Mol Case Stud* 5(1), 2/2019. e-Pub 2/2019. PMID: PMC6371746.
194. Boddu PC, Kadia TM. Molecular pathogenesis of acquired aplastic anemia. *Eur J Haematol* 102(2):103-110, 2/2019. e-Pub 12/2018. PMID: 30380171.
195. Kadia TM, Kantarjian HM, Konopleva M. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. *Oncotarget* 10(12):1250-1265, 2/2019. e-Pub 2/2019. PMID: PMC6383813.
196. Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. *Blood Adv* 3(6):851-861, 3/2019. PMID: PMC6436011.
197. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian H, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. *Cancer*. e-Pub 3/2019. PMID: PMC6742577.
198. Boddu P, Thakral B, Alhurajji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. *J Clin Pathol* 72(3):251-257, 3/2019. e-Pub 11/2018. PMID: 30467242.
199. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. *Cancer Discov* 9(3):370-383, 3/2019. e-Pub 11/2018. PMID: PMC6397669.
200. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. *Blood Adv* 3(6):922-933, 3/2019. PMID: PMC6436014.
201. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 19(3):142-148.e1, 3/2019. e-Pub 12/2018. PMID: 30635233.
202. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. *Blood* 133(10):1011-1019, 3/2019. e-Pub 12/2018. PMID: PMC6405333.
203. Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. *Cancer* 125(7):1091-1100, 4/2019. e-Pub 12/2018. PMID: PMC6561101.
204. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V,

- Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. *N Engl J Med* 380(22):2095-2103, 5/2019. PMID: 31141631.
205. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. *Cancer* 125(10):1665-1673, 5/2019. e-Pub 1/2019. PMID: 30668890.
 206. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. *Cancer* 125(11):1855-1866, 6/2019. e-Pub 2/2019. PMID: 30811597.
 207. Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. *Leuk Lymphoma*:1-4. e-Pub 6/2019. PMID: 31246142.
 208. Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated AML. *Am J Hematol* 94(6):E158-E160, 6/2019. e-Pub 3/2019. PMCID: PMC6602057.
 209. Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. *Am J Hematol*. e-Pub 6/2019. PMID: 31237017.
 210. Saenz DT, Fiskus W, Manshoury T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β -catenin as therapy for post-myeloproliferative neoplasm secondary AML. *Leukemia* 33(6):1373-1386, 6/2019. e-Pub 12/2018. PMID: 30575820.
 211. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. *Am J Hematol* 94(7):E188-E190, 7/2019. e-Pub 4/2019. PMCID: PMC6566858.
 212. Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N. *Plesiomonas shigelloides* gastroenteritis in a patient with chronic lymphocytic leukemia. *Leuk Lymphoma*:1-2. e-Pub 7/2019. PMID: 31305193.
 213. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. *Blood* 134(1):59-73, 7/2019. e-Pub 4/2019. PMCID: PMC6609954.
 214. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. *Cancer* 125(15):2579-2586, 8/2019. e-Pub 4/2019. PMCID: PMC6625850.
 215. Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes

- after hypomethylating-agent failure. *Leuk Lymphoma* 60(9):1-7, 9/2019. e-Pub 2/2019. PMID: 30773968.
216. Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. *Hematol Oncol Stem Cell Ther* 12(3):161-165, 9/2019. e-Pub 8/2017. PMID: 28830803.
 217. Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. Emerging drug profile: CPX-351 (vyxeos) in AML. *Leuk Lymphoma*:1-10. e-Pub 9/2019. PMID: 31547736.
 218. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. *Lancet Haematol* 6(9):e480-e488, 9/2019. e-Pub 8/2019. PMCID: PMC6778960.
 219. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. *Cancer* 125(18):3219-3224, 9/2019. e-Pub 5/2019. PMID: 31150121.
 220. Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. *J Clin Oncol* 37(29):2632-2642, 10/2019. e-Pub 8/2019. PMID: 31430225.
 221. Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. *Blood* 134(14):1132-1143, 10/2019. e-Pub 7/2019. PMCID: PMC7042666.
 222. Tanaka T, Morita K, Wang F, Little L, Gumbs C, Matthews J, DiNardo CD, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Garcia-Manero G, Futreal PA, Takahashi K. Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). *Blood* 134(Supplement_1):17, 11/2019. PMID: 31724013.
 223. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). *Blood* 134(Supplement_1):34, 11/2019. PMID: 31724006.
 224. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian H, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. *Cancer*. e-Pub 11/2019. PMID: 31742675.
 225. Molica M, Breccia M, Foa R, Jabbour E, Kadia TM. Maintenance therapy in AML: The past, the present and the future. *Am J Hematol* 94(11):1254-1265, 11/2019. e-Pub 9/2019. PMID: 31429099.
 226. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in

- patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. *Cancer* 125(21):3755-3766, 11/2019. e-Pub 7/2019. PMID: 31310323.
227. Messer A, Brown AE, Pacha O, Boddu P, Geppner A, Kadia TM, Huen AO. Successful treatment of cutaneous adult T-cell leukemia/lymphoma with imiquimod. *JAAD Case Rep* 5(11):979-981, 11/2019. e-Pub 10/2019. PMCID: PMC6835029.
 228. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. *Am J Hematol*. e-Pub 11/2019. PMID: 31682008.
 229. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. *Leuk Lymphoma* 60(13):3172-3180, 12/2019. e-Pub 5/2019. PMID: 31125272.
 230. Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. *Am J Hematol* 94(12):1388-1395, 12/2019. e-Pub 10/2019. PMID: 31595534.
 231. Paul S, DiPippo AJ, Ravandi F, Kadia TM. Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. *Future Oncol* 15(34):3885-3894, 12/2019. e-Pub 9/2019. PMID: 31559849.
 232. Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ. Treatment-free remission in chronic myeloid leukemia. *Clin Adv Hematol Oncol* 17(12):686-696, 12/2019. PMID: 31851157.
 233. Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver N. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. *Cancer Manag Res* 11:8817-8828, 2019. e-Pub 10/2019. PMCID: PMC6782026.
 234. Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). *Leuk Lymphoma* 61(2):1-5, 2/2020. e-Pub 9/2019. PMID: 31566032.
 235. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. *Blood Adv* 4(3):482-495, 2/2020. PMCID: PMC7013259.
 236. Rausch CR, Jabbour EJ, Kantarjian HM, Kadia TM. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. *Cancer* 126(6):1152-1160, 3/2020. e-Pub 12/2019. PMID: 31794095.
 237. Molica M, Breccia M, Capria S, Trisolini S, Foa R, Jabbour E, Kadia TM. The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. *Leuk Lymphoma* 61(3):536-545, 3/2020. e-Pub 11/2019. PMID: 31752577.
 238. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. *Blood Adv* 4(8):1690-1699, 4/2020. PMCID: PMC7189295.
 239. Reville PK, Kadia T. Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia. *Curr Treat Options Oncol* 21(4):34, 4/2020. e-Pub 4/2020. PMID: 32318829.
 240. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid

- Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. *Clin Infect Dis.* e-Pub 4/2020. PMID: 32236406.
241. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. *Cancer* 126(7):1448-1459, 4/2020. e-Pub 1/2020. PMID: 31999850.
 242. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. *Cancer* 126(7):1502-1511, 4/2020. e-Pub 1/2020. PMID: 31999839.
 243. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting the β -catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. *Blood* 135(15):1255-1269, 4/2020. PMCID: PMC7146021.
 244. Lachowicz CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. *Blood Adv* 4(7):1311-1320, 4/2020. PMCID: PMC7160266.
 245. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. *Acta Haematol*:1-7. e-Pub 4/2020. PMID: 32289808.
 246. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. *Blood Cancer J* 10(5):47, 5/2020. e-Pub 5/2020. PMCID: PMC7198507.
 247. Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. *Blood Cancer J* 10(5):48, 5/2020. e-Pub 5/2020. PMCID: PMC7198530.
 248. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. *Cancer* 126(10):2193-2205, 5/2020. e-Pub 3/2020. PMID: 32125707.
 249. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. *Acta Haematol*:1-13. e-Pub 5/2020. PMID: 32392559.
 250. Yilmaz M, Kadia T, Ravandi F. Identifying effective drug combinations for patients with acute myeloid leukemia. *Expert Rev Anticancer Ther*:1-11. e-Pub 6/2020. PMID: 32552126.
 251. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. *Am J Hematol* 95(6):612-622, 6/2020. e-Pub 3/2020. PMID: 32112433.

252. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. *Haematologica*. e-Pub 6/2020. PMID: 32499238.
253. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. *Leukemia*. e-Pub 6/2020. PMID: 32561839.
254. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. *Am J Hematol*. e-Pub 6/2020. PMID: 32557828.
255. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. *Lancet Haematol* 7(7):e523-e533, 7/2020. PMID: 32589978.
256. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. *Am J Hematol* 95(7):734-739, 7/2020. e-Pub 4/2020. PMID: 32170867.
257. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. *Leukemia* 34(9):2489-2492, 9/2020. e-Pub 2/2020. PMID: 32099037.
258. Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. *Mod Pathol* 33(9):1678-1689, 9/2020. e-Pub 4/2020. PMID: 32238878.
259. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. *Am J Hematol* 95(9):E225-E228, 9/2020. e-Pub 5/2020. PMID: 32356320.
260. Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. *Haematologica Online ahead of print*, 9/2020. e-Pub 9/2020. PMID: 33054123.
261. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson

- PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. *Lancet Haematol* 7(10):e724-e736, 10/2020. e-Pub 9/2020. PMID: PMC7549397.
262. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. *J Hematol Oncol* 13(1):132, 10/2020. e-Pub 10/2020. PMID: PMC7542942.
263. Samra B, Kantarjian HM, Sasaki K, Alotaibi AS, Konopleva M, O'Brien S, Ferrajoli A, Garris R, Nunez CA, Kadia TM, Short NJ, Jabbour E. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. *Acta Haematol*:1-8. e-Pub 11/2020. PMID: 33238261.
264. Pandey RK, DiPippo A, Kadia T, Pemmaraju N, Workeneh BT, Jabbour E, Ravandi F, Jain N. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. *Leuk Lymphoma* 61(11):1-3, 11/2020. e-Pub 7/2020. PMID: 32654562.
265. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. *Am J Hematol* 95(11):1296-1303, 11/2020. e-Pub 8/2020. PMID: 32697348.
266. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. *Am J Hematol* 95(11):1288-1295, 11/2020. e-Pub 8/2020. PMID: 32681739.
267. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. *Leukemia* 34(11):2914-2924, 11/2020. e-Pub 6/2020. PMID: 32546726.
268. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. *Blood Adv* 4(22):5681-5689, 11/2020. PMID: PMC7686900.
269. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 20(11):e871-e882, 11/2020. e-Pub 6/2020. PMID: 32792304.
270. Jammal N, Rausch CR, Kadia TM, Pemmaraju N. Cell cycle inhibitors for the treatment of acute myeloid leukemia: A review of phase 2 & 3 clinical trials. *Expert Opin Emerg Drugs* 25(4):1-9, 12/2020. e-Pub 11/2020. PMID: 33161749.
271. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). *Am J Hematol* 95(12):E326-E329, 12/2020. e-Pub 10/2020. PMID: 32886803.
272. Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H,

- Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. *Blood Adv* 4(24):6117-6126, 12/2020. PMID: PMC7757010.
273. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. *Leuk Lymphoma* 61(13):1-8, 12/2020. e-Pub 8/2020. PMID: 32755333.
274. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. *Am J Hematol*. e-Pub 12/2020. PMID: 33264443.
275. Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. *Front Oncol* 10:588876, 2020. e-Pub 10/2020. PMID: PMC7606916.
276. Reville PK, Kadia TM. Maintenance Therapy in AML. *Front Oncol* 10:619085, 2020. e-Pub 2/2021. PMID: PMC7884813.
277. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. *Front Oncol* 10:582213, 2020. e-Pub 1/2021. PMID: PMC7878971.
278. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. *Cancer*. e-Pub 1/2021. PMID: 33449377.
279. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. *Leuk Lymphoma* 62(1):1-5, 1/2021. e-Pub 9/2020. PMID: 32955970.
280. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. *Blood Cancer J* 11(2):41, 2/2021. e-Pub 2/2021. PMID: PMC7900255.
281. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. *Cancer* 127(3):381-390, 2/2021. e-Pub 10/2020. PMID: 33119202.
282. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. *Am J Hematol* 96(2):E50-E53, 2/2021. e-Pub 11/2020. PMID: 33156969.
283. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. *Am J Hematol*. e-Pub 2/2021. PMID: 33580980.

284. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. *Br J Haematol*. e-Pub 2/2021. PMID: 33618432.
285. Wilson NR, Fang H, Loghavi S, Wang W, Tang G, Haltom RO, Rausch CR, McClain KL, Rao KV, Popat UR, Fayad LE, Champa N, Calvo KR, Allen CE, Kadia TM, Pemmaraju N. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. *Br J Haematol* 192(3):667-671, 2/2021. e-Pub 11/2020. PMID: 33238033.
286. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. *Blood Cancer J* 11(2):25, 2/2021. e-Pub 2/2021. PMID: PMC7873265.
287. Reville, P, Kantarjian,H, Ravandi, F, Jabbour E, DiNardo CD, Daver N, Pemmaraju, N, Ohanian M, Alvarado Y, Xiao, L, Alatrash G, Loghavi, S, Rausch CR, Borthakur G, Konopleva M, Cortes, J, Kadia, TM. Nivolumab Maintenance in High-Risk Acute Myeloid Leukemia Patients: A Single-Arm, Open-Label, Phase II Study. *Blood Cancer J* (2021) (*Accepted*)
288. Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx K, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian H, and Kadia TM. Outcomes in Patients with Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia with or without Venetoclax-Based Therapy. *Cancer* (2021) (*Under Review*)
289. Abbas HA, Reville PK, Geppner A, Rausch C, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo CS, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. *Leukemia and Lymphoma* (2021) (*Under Review*)
290. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, and Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. *Lancet Haematology* (2021) (*Under Review*)
291. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Jabbour E, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian H. Intensive Chemotherapy with Cladribine, Idarubicin, Cytarabine (CLIA) Combined with Venetoclax in Newly Diagnosed Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome. *JAMA Oncology* (2021) (*Submitted*)

Invited Articles

N/A

Editorials

1. Kanagal-Shamanna R, Jain P, Luthra R, Patel KP, Garcia-Manero G, Takahashi K, Ravandi F, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Estrov Z, Wierda WG, O'Brien SM, Cortes JE, Kantarjian HM, Jabbour EJ. Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. *Blood* 128(22):2917, 12/2016.

Other Articles

1. **Kadia, T**, Jabbour E, O'Brien S. Treatment Strategies for Chronic Lymphocytic Leukemia. *Oncology*, 1/2006. e-Pub .

2. **Kadia, T.** Chronic Lymphocytic Leukemia: New Insights Lead to More Refined, Individualized Treatment. *Molecular Oncology*, 1/2007. e-Pub .

Abstracts

1. Borthakur G, Ishizawa J, DiNardo CD, Kadia TM, Weise K, Allen JE, Oster W, Cortes JE, Kantarjian HM, Andreeff M. A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias. *Blood* 128(22):3997, 12/2016.
2. Montalban-Bravo G, Huang X, Jabbour EJ, Borthakur G, DiNardo CD, Pemmaraju N, Cortes JE, Verstovsek S, Kadia TM, Daver NG, Wierda WG, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso Pierola A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos CE, Pierce S, Estey EH, Bohannan ZS, Kantarjian HM, Garcia-Manero G. A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials. *Blood* 128(22):1999, 12/2016.
3. Jabbour EJ, Short NJ, Huang X, Maiti A, Kadia TM, Daver N, Borthakur G, DiNardo CD, Pemmaraju N, Sasaki K, Estrov Z, Verstovsek S, Ravandi F, Alvarado Y, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Miller D, Dong X, Kantarjian HM, Garcia-Manero G. A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. *Blood* 128(22):226, 12/2016.
4. Short NJ, Kantarjian HM, Jorgensen JL, Ravandi F, Yilmaz M, Khouri MR, Wang S, Thomas DA, Khoury JD, Champlin RE, Khouri IF, Kebriaei P, Marin D, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, DiNardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Jabbour EJ. Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. *Blood* 128(22):2916, 12/2016.
5. Alfonso Pierola A, Montalban-Bravo G, Takahashi K, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome. *Blood* 128(22):3177, 12/2016.
6. Jain P, Wang S, Kantarjian HM, Sarwari N, Patel KP, Bose P, Pierce S, Kadia TM, Daver N, Pemmaraju N, Cortes JE, Verstovsek S. Aleukemic Mast Cell Leukemia (aMCL) - Clinical Characteristics and Outcomes. *Blood* 128(22):4255, 12/2016.
7. Benton CB, Takahashi K, Bose P, Wang F, Chen HC, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa GC, Daver N, Jabbour EJ, DiNardo CD, Bueso-Ramos CE, Patel K, Kornblau SM, Konopleva M, Borthakur G, Kadia TM, Cortes JE, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, Kantarjian HM. Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. *Blood* 128(22):597, 12/2016.
8. Yohannan Sam P, Ahaneku H, Noguera-Gonzalez GM, Jabbour E, Garcia-Manero G, Borthakur G, Wierda WG, Daver N, Kadia T, Burger J, Pierce S, DiNardo CD, Ravandi F, Kantarjian HM, Cortes JE. Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). *Blood* 128(22):1919, 12/2016.
9. Boddu PC, Kantarjian HM, Garcia-Manero G, Verstovsek S, Ravandi F, Jabbour EJ, Takahashi K, Bhalla KN, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and Outcomes of Older Patients with Secondary AML According to Treatment Approach. *Blood* 128(22):2788, 12/2016.
10. Aoki E, Jain P, Ferrajoli A, Estrov Z, Keating M, O'Brien SM, Wierda WG, Jain N, Thompson PA, Jabbour E, Pierce S, Hosing C, Kantarjian HM, Ravandi F, Kadia TM. Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience. *Blood* 129(22):2997, 12/2016.
11. Jain P, Kantarjian HM, Ravandi F, Jabbour E, Daver N, Pemmaraju N, DiNardo CD, Alvarado Y, Jain N, Borthakur G, Verstovsek S, Ferrajoli A, Ohanian M, Konopleva M, Naqvi K, Fitch

- T, Garcia-Manero G, Cortes JE, Estrov Z, Kadia TM. Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤ 65 yrs) with Acute Myeloid Leukemia. *Blood* 128(22):1639, 12/2016.
12. Jain P, Kantarjian HM, Ravandi F, Kanagal-Shamanna R, Khoury JD, Patel KP, Garcia-Manero G, Konopleva M, Jain N, Sasaki K, Kadia TM, Borthakur G, Garris R, Pierce S, Estrov Z, Wierda WG, Cortes JE, O'Brien SM, Jabbour EJ. Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens. *Blood* 128(22):2779, 12/2016.
 13. Montalban-Bravo G, Takahashi K, Wang F, Konopleva M, Xingzhi S, Gonzalez GN, Huang X, Pierola AA, Jabbour EJ, Colla S, Borthakur G, Daver N, DiNardo CD, Estrov Z, Kadia TM, Pemmaraju N, Ravandi F, Bueso-Ramos CE, Chamseddine AN, Zhang J, Kantarjian HM, Patel K, Chin L, Futreal A, Garcia-Manero G. Clinical Relevance of Driver Mutations and Number of Driver Mutations in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. *Blood* 128(22):54, 12/2016.
 14. Jabbour EJ, Kantarjian HM, Sasaki K, Kadia TM, Ravandi F, Cortes JE, Khoury JD, Patel K, Bueso-Ramos CE, Daver NG, Borthakur G, Jain N, DiNardo CD, Konopleva M, Verstovsek S, Pemmaraju N, Estrov Z, Miller D, Maduik R, Faderl S, Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. *Blood* 128(22):3166, 12/2016.
 15. Chamoun K, Kantarjian HM, Rios MB, Assi R, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia TM, Pemmaraju N, Jabbour EJ, Cortes JE. CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US. *Blood* 128(22):1923, 12/2016.
 16. Ohanian M, Garcia-Manero G, Jabbour EJ, Daver N, Borthakur G, Kadia TM, Brandt M, Pierce S, Burger J, Richie MA, Patel K, Cortes JE, Kantarjian HM, Ravandi F. Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITD mutation. *Blood* 128(22):1611, 12/2016.
 17. Assi R, Kantarjian HM, Verstovsek S, Garcia-Manero G, Konopleva M, Ravandi F, DiNardo CD, Kadia TM, Daver N, Jabbour EJ, Gborogen RA, Chamoun K, Wierda WG, Borthakur G, Cortes JE. CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia. *Blood* 128(22):4047, 12/2016.
 18. Jain N, Ravandi F, Garcia-Manero G, Borthakur G, Kadia TM, Jabbour EJ, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Alvarado Y, Takahashi K, Benton CB, Pike A, Pierce S, Cortes JE, Kantarjian HM. Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). *Blood* 128(22):2817, 12/2016.
 19. Jain N, Basu S, Thakral B, Burger J, Thompson PA, Ferrajoli A, Estrov Z, Bueso-Ramos CE, Stingo F, Bassett Jr., RL, Daver N, Kadia TM, Matthews J, Flores W, Somani N, Blando J, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL). *Blood* 128(22):2012, 12/2016.
 20. Thompson PA, Strati P, Keating M, O'Brien SM, Ferrajoli A, Burger JA, Jorgensen JL, Faderl S, Estrov Z, Jain N, Kadia T, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Wierda WG. Early Achievement of MRD-Negativity in IGHV-Mutated (IGHV-M) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Subsequent Clinical Relapse. *Blood* 128(22):232, 12/2016.
 21. Ohanian M, Kantarjian HM, Borthakur G, Kadia TM, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour EJ, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt JR, Ravandi F, Cortes JE. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. *Blood* 128(22):2744, 12/2016.

22. Jain P, Casteel D, Allen CE, McClain KL, Wang S, Konoplev S, Jabbour EJ, Gonzalez GN, Huang X, Miller S, Abdelall W, Tamamyian G, Kadia TM, Borthakur G, Estrov Z, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian HM, Daver N. Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation. *Blood* 128(22):2791, 12/2016.
23. Jain P, Kantarjian HM, Jabbour EJ, Gonzalez GN, Garcia-Manero G, Kanagal-Shamanna R, Patel KP, Hu S, DellaSala SE, Pierce S, Sasaki K, Konopleva M, Wierda WG, Daver N, Kadia TM, Borthakur G, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. *Blood* 128(22):1220, 12/2016.
24. Sasaki K, Kantarjian HM, Ravandi F, Daver N, Kadia TM, Khouri RB, Alvarado Y, Burger JA, Thomas DA, Garcia-Manero G, DiNardo CD, Pemmaraju N, Short NJ, Schroeder H, Garriss R, Bose P, Jain N, Naqvi K, Wierda WG, Verstovsek S, Cortes JE, Konopleva M, O'Brien SM, Jabbour EJ. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. *Blood* 128(22):2783, 12/2016.
25. Montalban-Bravo G, Takahashi K, Pierola AA, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Nogueras-Gonzalez GM, Huang X, Bueso-Ramos CE, Futreal A, Kantarjian HM, Garcia-Manero G. Impact of Driver Mutations in Patients with Lower-Risk Myelodysplastic Syndromes Classified By the MD Anderson Lower-Risk Prognostic Scoring System. *Blood* 128(22):4317, 12/2016.
26. Alfonso Pierola A, Montalban-Bravo G, Chamseddine AN, Takahashi K, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Impact of the Next-Generation Sequencing Panel on Treatment Choice in Patients with Myelodysplastic Syndrome. *Blood* 128(22):4340, 12/2016.
27. Montalban-Bravo G, Alfonso Pierola A, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Nogueras-Gonzalez GM, Huang X, Bueso-Ramos CE, Patel K, Futreal A, Kantarjian HM, Takahashi K, Garcia-Manero G. Increased Number of Driver Mutations Is a Predictor of Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes. *Blood* 128(22):51, 12/2016.
28. Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau SM, Ohanian M, Alfonso Pierola A, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero GM. Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). *bLOOD* 128(22):346, 12/2016.
29. Boddu PC, Kantarjian HM, RashidShah A, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhurajji A, Burger J, Kornblau SM, Dellasala SE, Pierce S, Jabbour EJ, Cortes JE. Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting. *Blood* 128(22):3073, 12/2016.
30. Alfonso Pierola A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Pierce S, Kantarjian HM, Garcia-Manero G. Long-Term Experience with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia. *Blood* 128(22):111, 12/2016.
31. Montalban-Bravo G, Alfonso Pierola A, Takahashi K, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Pierce S, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero G. Myelodysplastic Syndromes with NPM1Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. *Blood* 128(22):3171, 12/2016.

32. Sasaki K, Jabbour EJ, O'Brien SM, Thomas DA, Ravandi F, Garcia-Manero G, Cortes JE, Short NJ, Verstovsek S, Yilmaz M, Wierda WG, Borthakur G, Kadia TM, Konopleva M, Khouri MR, Ferrajoli A, Daver NG, Pemmaraju N, DiNardo CD, Jain N, Benton CB, Takahashi K, Naqvi K, Bose P, Kornblau SM, Andreeff M, Keating MJ, Freireich EJ, Kantarjian HM. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. *Blood* 128(22):1975, 12/2016.
33. Abaza Y, Jabbour EJ, Verstovsek S, Estrov Z, Ravandi F, Borthakur G, Kadia TM, Daver N, DiNardo CD, Bueso-Ramos CE, Hidalgo JE, Schneider H, Montalban-Bravo G, Alfonso A, Wei Y, Kantarjian HM, Garcia-Manero G. Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy. *Blood* 128(22):4318, 12/2016.
34. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Zhang C, Ravandi F, Plunkett W. Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study. *Blood* 128(22):2822, 12/2016.
35. Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Brandt M, Pierce S, Noguera-Gonzalez GM, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. *Blood* 128(22):4262, 12/2016.
36. Abaza Y, Kantarjian HM, Jabbour EJ, Thomas DA, Kadia TM, Borthakur G, Burger J, Wierda WG, Jain N, Faderl S, O'Brien SM, Konopleva M, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Kelly MA, Garris R, Garcia-Manero G, Cortes JE, Ravandi F. Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. *Blood* 128(22):177, 12/2016.
37. Sasaki K, Jabbour EJ, Ravandi F, Daver NG, Pemmaraju N, Thomas DA, Khouri RB, Yilmaz M, Kadia TM, Short NJ, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda WG, Jeanis TV, Cortes JE, O'Brien SM, Kantarjian HM. Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. *Blood* 128(22):757, 12/2016.
38. Sasaki K, Jabbour EJ, O'Brien SM, Ravandi F, Thomas DA, Kadia TM, Garcia-Manero G, Burger JA, Pemmaraju N, Alvarado Y, Daver NG, Jain N, Konopleva M, Champlin RE, Khouri IF, Kebriaei P, Marin D, DiNardo CD, Estrov Z, Takahashi K, Short NJ, Khouri MR, Jacob J, Garris R, Cortes JE, Kantarjian hm. Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). *Blood* 128(22):1606, 12/2016.
39. Alhurajji A, Kantarjian HM, Jabbour EJ, Boddu PC, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia TM, Pemmaraju N, Pierce S, Garcia-Manero G, Cortes JE. Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors. *Blood* 128(22):3064, 12/2016.
40. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia TM, Cortes JE, Daver N, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Konopleva M, Pierce S, Patel KP, Kornblau SM, Kantarjian HM, Young KH, Garcia-Manero G, Andreeff M. Pure Erythroid Leukemia Is Characterized By TP53 mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. *Blood* 128(22):2952, 12/2016.
41. Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia TM, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. *Blood* 128(22):1612, 12/2016.
42. Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, Kadia TM, Garcia-Manero G, DiNardo CD, Bose P, Pierce S, Zhou L, Estrov Z, Tuttle CK, Salinas K, Mak PY, Verstovsek S.

- Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). *Blood* 128(22):3105, 12/2016.
43. Montalban-Bravo G, Takahashi K, Alfonso Pierola A, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Nogueras-Gonzalez GM, Huang X, Bueso-Ramos CE, Futreal A, Kantarjian HM, Garcia-Manero G. STAG2 Mutations Are an Independent Prognostic Factor in Patients with Myelodysplastic Syndromes. *Blood* 128(22):3182, 12/2016.
 44. Chihara D, Kantarjian HM, Newberry KJ, Ravandi F, Daver NG, Bose P, DiNardo CD, Pemmaraju N, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Popat UR, Cortes JE, Verstovsek S. Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. *Blood* 128(22):1940, 12/2016.
 45. Abdelall W, Kantarjian HM, Borthakur G, Garcia-Manero G, Patel KP, Jabbour EJ, Daver NG, Kadia T, Gborogen RA, Konopleva M, Ravandi F, Andreeff M, Cortes JE. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. *Blood* 128(22):1642, 12/2016.
 46. Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar JK, Pemmaraju N, Borthakur G, Kadia TM, Konopleva M, Kantarjian HM, Cortes JE, Hearn KP, Reyes SR, Bueso-Ramos CE, Garcia-Manero G. Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-kb Activation. *Blood* 128(22):3191, 12/2016.
 47. Short NJ, Ravandi F, Huang X, Cortes JE, Pemmaraju N, Daver N, Khouri RB, Borthakur G, Jain N, Konopleva M, Estrov Z, Garcia-Manero G, Kadia TM, Wierda WG, DiNardo CD, O'Brien SM, Shah S, Pike A, Brandt M, Kantarjian HM, Jabbour EJ. Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood* 128(22):1067, 12/2016.
 48. Short NJ, Ravandi F, Huang X, Cortes JE, Pemmaraju N, Daver N, Khouri RB, Borthakur G, Jain N, Konopleva M, Estrov Z, Garcia-Manero G, Kadia TM, Wierda WG, DiNardo CD, O'Brien SM, Shah S, Pike A, Brandt M, Kantarjian HG, Jabbour EJ. Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood* 128(22), 12/2016.
 49. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Daver N, Deborah A Thomas, Pemmaraju N, Rita Khouri, Joseph David Khoury, Jorgensen JL, Alvarado Y, Sasaki K, Marina Konopleva, Garcia-Manero G, Kadia T, Cortes JE, Benton CB, Borthakur G, Burger JA, Ohanian M, Wierda WG, Estrov Z, Kornblau S, DiNardo CD, Ferrajoli A, Jovitta Jacob, Ameena Manzoor, Garris R, O'Brien SM and Jabbour EJ. A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. *Blood* 130(Suppl 1):2576, 12/2017.
 50. Short NJ, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau S, Ohanian M, Yvonne Gaisor, Richie MA, Pierce S, Jabbour EJ, Cortes JE and Ravandi F. A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia. *Blood* 130(Suppl 1):2577, 12/2017.
 51. Issa GC, Kantarjian HM, Wang F, González GN, Borthakur G, Tang G, Bueso-Ramos CE, Kanagal-Shamanna R, Hidalgo Lopez JE, Zhao C, Coyle M, Takahashi K, Preetesh J, Ravandi F, Kadia T, Garcia-Manero G, Jabbour EJ, Futreal A and Cortes JE. Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML. *Blood* 130(Suppl 1):47, 12/2017.
 52. Issa GC, Kantarjian HM, Gonzalez NG, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E and Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. *Blood* 130(Suppl 1):2091, 12/2017.

53. Naqvi K, Guillermo Montalban Bravo, Pierola AA, Yilmaz M, Sasaki K, Short NJ, Assi R, Jabbour EJ, Ravandi F, Benton CB, Tapan Kadia, Pierce S, Borthakur G, NavalDaver, DiNardo CD, Takahashi K, Jain N, Pemmaraju N, Graciela Nogueras González, Kantarjian HM, Garcia-Manero G. Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. *Blood* 130(Suppl 1):4258, 12/2017.
54. Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour EJ, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ and Wierda WG. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. *Blood* 130(Suppl 1):429, 12/2017.
55. Yilmaz M, Jabbour EJ, Wang X, Loghavi S, Joseph David Khoury, Jorgensen JL, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Maria Khouri, Jain N, Verstovsek S, Estrov Z, Estrov Z, Bose P, SherryPierce, Garris R, O'Brien SM and Kantarjian HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). *Blood* 130(Suppl 1):1434, 12/2017.
56. Assi R, Kantarjian HM, Cortes JE, Kadia T, Pemmaraju N, Jabbour EJ, Jain N, Daver N, Taisuke Uehara, Takashi Owa and Borthakur G. Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). *Blood* 130(Suppl 1):1380, 12/2017.
57. Maiti A, Kantarjian HM, Ravandi F, Maria Khouri, Deborah A Thomas, Garcia-Manero G, Rebecca Garris, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, MarinaKonopleva, Sasaki K, Ghayas C. Issa, Marie Ghosn, Heather M Schroeder, Tapan Kadia, Naval Daver, Susan M.O'Brien and Jabbour EJ. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. *Blood* 130(Suppl 1):3876, 12/2017.
58. Pierola AA, Assi R, Devendra KC, Abaza Y, Abdallah Abou Zahr, Chamoun K, GuillermoMontalban-Bravo, Takahashi K, Jabbour EJ, Tapan Kadia, Ravandi F, Cortes JE, DiNardo CD, Naval Daver, Borthakur G, Pemmaraju N, Konopleva M, Carlos E. Bueso-Ramos, Keyur P.Patel, Andrew Futreal, Pierce S, Kantarjian HM and Garcia-Manero G. Impact of Next-Generation Sequencing on Treatment Choices for Patients with Acute Myeloid Leukemia. *Blood* 130(Suppl 1):3852, 12/2017.
59. Jain N, Cortes JE, Ravandi F, Konopleva M, Alvarado Y, Kadia T, Wierda WG, Borthakur G, Naqvi K, Pemmaraju N, DiNardo CD, Daver N, Yilmaz M, Patel K, Linderman DB, Garris R, Jabbour EJ and Kantarjian HM. Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase. *Blood* 130(Suppl 1):143, 12/2017.
60. Pemmaraju N, Carter BZ, Kantarjian HM, Bose P, Kadia T, Jabbour EJ, DiNardo CD, Daver N, Estrov Z, Cortes JE, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle CK, Pierce S, Popat U and Verstovsek S. Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. *Blood* 130(Suppl 1):256, 12/2017.
61. Ghorab A, Preetesh J, Kantarjian HM, Kanagal-Shamanna R, Jabbour EJ, Sasaki K, Kadia T, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, SrdanVerstovsek, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. *Blood* 130(Suppl 1):2868, 12/2017.
62. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Pemmaraju N, Devendra KC, Pierce S, Patel KP, Konopleva M, Ravandi F, Garcia-Manero G, Kadia T, Cortes JE, Kantarjian HM, Andreeff M and Verstovsek S. JAK2 Variants Associated with Secondary-AML from MPN. *Blood* 130(Suppl 1):305, 12/2017.
63. Assi R, Benton CB, Ahmed Al Rawi, Chamoun K, Wang F, Pierce S, Patel KP, Betty K. Hamilton, DiNardo CD, Garcia-Manero G, Kantarjian HM, Kadia T, SrdanVerstovsek and

- Andreeff M. JAK3 Variants in Adults with Myeloid Malignancies and Potential for Response to JAK3 Inhibition. *Blood* 130(suppl 1):1381, 12/2017.
64. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J and Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. *Blood* 130(Suppl 1):1275-1283, 12/2017.
 65. Chamoun K, Kantarjian HM, Mary Abisola Akosile, Assi R, Ravandi F, Borthakur G, Garcia-Manero G, Kadia T, Konopleva M, Estrov Z, DiNardo CD, Daver N, Pemmaraju N, Ferrajoli A, Burger JA, Wierda W, Jabbour EJ and Cortes JE. Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience. *Blood* 130(Suppl 1):1594, 12/2017.
 66. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. *Blood* 130(Suppl 1):2584-2587, 12/2017.
 67. Daver N, Garcia-Manero G, Sreyashi Basu, Cortes JE, Ravandi F, Jabbour EJ, Assi R, Brandt M, Pierce S, Tauna Gordon, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, Wilmer Flores, Jairo Matthews, DiNardo CD, Borthakur G, Konopleva M, JamesAllison, Padmanee Sharma and Kantarjian HM. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML. *Blood* 130(Suppl 1):1345, 12/2017.
 68. Pemmaraju N, Prajwal Boddu, Kantarjian HM, Ravandi F, Marcos De Lima, Richard E. Champlin, Gabriela Rondon, Tapan Kadia, Jabbour EJ, Garcia-Manero G, Cortes JE and Muzaffar H.Qazilbash. Outcomes after Third Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Acute and Chronic Leukemias. *Blood* 130(Suppl 1):5551, 12/2017.
 69. Prajwal Boddu, Kantarjian HM, Ravandi F, Jabbour EJ, Naval Daver, Pemmaraju N, DiNardo CD, Verstovsek S, Alvarado Y, Borthakur G, Jain N, Konopleva M, Christopher BBenton, Slack R, Patel KP, Garcia-Manero G, Cortes JE, Kadia T. Outcomes By Treatment Setting and Genomic Profile in Patients with AML on Cladribine, Idarubicin, and Cytarabine. *Blood* 130(Suppl 1):3898, 12/2017.
 70. Preetesh Jain, Kanagal-Shamanna R, Kantarjian HM, F. Anthony San Lucas,. Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML. *Blood* 130(Suppl 1), 12/2017.
 71. Kiyomi Morita, Wang F, Patel K, Bueso-Ramos C, Issa GC, Xingzhi Song, Jianhua Zhang, Samantha Tippen, Rebecca Thornton, Coyle M, Latasha Little, Curtis Gumbs, Ravandi F, Kadia T, Daver N, Konopleva M, Andreeff M, Cortes JE, Garcia-Manero G, Jabbour EJ, Andrew Futreal, Kantarjian HM and Takahashi K. Persistent Somatic Mutation at Remission Is Associated with Poor Survival and Higher Risk of Relapse in Patients with Acute Myeloid Leukemia. *Blood* 130(Suppl 1):2667, 12/2017.
 72. Ravandi F, Daver N, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia T, Boddu PC, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Wilmer Flores, Sreyashi Basu, James Allison, PadmaneeSharma, Pierce S, Brandt M, Allison Pike, Cortes JE and Kantarjian HM. Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood* 130(Suppl 1):815, 12/2017.
 73. Daver N, Boddu P, Garcia-Manero G, Ravandi F, Jabbour EJ, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Kadia T, Jain N, Pierce S, Wilmer Flores, Kornblau S, Nawar Hussain, Ning J, González GN, Sreyashi Basu, Cortes JE, PadmaneeSharma and Kantarjian HM. Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML. *Blood* 130(Suppl 1):2634, 12/2017.
 74. Borthakur G, Kantarjian HM, DiNardo CD, Daver N, Jabbour EJ, Kadia T, Garcia-Manero G, Ravandi F, Pemmaraju N, Konopleva M, Ohanian M, Wierda WG, Jain N, Lian-Chun Xiao, Paromita Mukherjee, Brandt M and Cortes JE. Phase II Study of CPX-351 (Cytarabine:

- Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality. *Blood* 130(Suppl 1):892, 12/2017.
75. Sasaki K, Jabbour EJ, Maria Khouri, Deborah A Thomas, Garcia-Manero G, Ravandi F, Borthakur G, Short NJ, Issa GC, Kadia T, Emily Jones, Garris R, Cortes JE, Susan M.O'Brien and Kantarjian HM. Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). *Blood* 130(Suppl 1):2554, 12/2017.
 76. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Pierce S, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade. *Blood* 130(Suppl 1):3209, 12/2017.
 77. Mrinal M. Patnaik, Ana Alfonso, Fevzi Yalniz, Kadia TM, Rangit Vallapureddy, Jabbour E, Terra L. Lasho, Curtis A. Hanson, Kantarjian HM, Ayalew Tefferi and Garcia-Manero G. Prognostic Factors and Survival Outcomes in Blast Transformed Chronic Myelomonocytic Leukemia: A Mayo Clinic-MD Anderson Cancer Center Study of 171 Cases. *Blood* 130(Suppl 1):2964, 12/2017.
 78. Boddu P, Swaminathan M, Ravandi F, Garcia-Manero G, Borthakur G, Jabbour EJ, DiNardo CD, Daver N, Jain N, Pemmaraju N, Jorgensen JL, Wang SA, Andreeff M, Cortes JE, Kantarjian HM and Kadia T. Prognostic Implications of Minimal Residual Disease Detection in Acute Myeloid Leukemia (AML) with Cytarabine Based Therapy of Differing Dose Intensities. *Blood* 130(Suppl 1):1419, 12/2017.
 79. Yilmaz M, Kantarjian HM, Wang X, Devendra KC, Joseph David Houry, Ravandi F, Nicholas JShort, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda WG, Maria Khouri, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, Susan M.O'Brien and Jabbour EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). *Blood* 130(Suppl 1):1435, 12/2017.
 80. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H and Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. *Blood* 130(Suppl 1):1514-1522, 12/2017.
 81. Burger JA, Sivina M, Ferrajoli A, Jain N, Kim E, Kadia T, Estrov Z, Nogueras González G, Huang X, Ohanian M,. Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood* 130(Suppl 1):427, 12/2017.
 82. Maliha Khan, Kantarjian HM, Ning J, Akosile M, Wen Li, Borthakur G, Jain N, DiNardo CD, Wierda WG, Ravandi F, Garcia-Manero G, Konopleva M, Kadia T, Pemmaraju N, Thompson PA, Daver N, Jabbour EJ and Cortes JE. Response and Outcomes of Third-Line Tyrosine Kinase Inhibitor Therapy on Patients with Chronic Phase Chronic Myeloid Leukemia. *Blood* 130(Suppl 1):2882, 12/2017.
 83. Boddu P, Gurguis C, Cortes JE, Akosile M, Ravandi F, Sanford D, Brandt M, Maduik R, Kadia T, Kantarjian HM and Borthakur G. Response Kinetics and Factors Predicting Survival Among Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML). *Blood* 130(Suppl 1):27, 12/2017.
 84. Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Rubenstein SE, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger S, Aleksandra Butrym, Gianluca Gaidano, Xavier Thomas, Pau Montesinos, David A. Rizzieri, Donald P. Quick, Edward Agura, Parameswaran Venugopal, JanakiramanSubramanian, Lori J. Maness, Daniel-Eric Robert, Yosr Hicheri, Kadia T, Ravandi F, Marc. Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. *Blood* 130(Suppl 1):891, 12/2017.
 85. Caitlin R Rausch, DiNardo CD, Kadia T, Takahashi K, Jain N, Benton CB, Philip AThompson, Ohanian M, Wendy Covert, Morgan Mace, Kayleigh Marx, Pemmaraju N, Daver N, Jabbour EJ, Cortes JE, Garcia-Manero G, Ravandi F, Konopleva M and Kantarjian HM. Results of

- Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies. *Blood* 130(Suppl 1):1356, 12/2017.
86. Jain N, Jabbour EJ, Patrick Zweider McKay, Ravandi F, Takahashi K, Kadia T, Wierda WG, Michael E. Rytting, Cesar Nunez, Patel K, Xinyan Lu, Tang G, Sergej Naumovich Konoplev, Sa A.Wang, Lina Han, Beenu Thakral, Kathryn G. Roberts, April Deshmukh, Garris R, Jorgensen JL, AntonioCavazos, Verstovsek S, Garcia-Manero G, O'Brien SM, Cortes JE, Charles G. Mullighan, Kantarjian HM and Konopleva M. Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial. *Blood* 130(Suppl 1):1322, 12/2017.
 87. Benton CB, Maliha Khan, Graciela Noguerras González, Aziz Nazha, Jin Piao, Ning J, Fleur M. Aung, Jabbour EJ, Tapan Kadia, Borthakur G, Ravandi F, Rami S. Komrokji, David P. Steensma, Amy E.DeZern, Gail J. Roboz, Mikkael A. Sekeres, Andreeff M, Kantarjian HM and Garcia-Manero G. Sequential Stratification Prognostic Score for Patients with Intermediate-Risk Myelodysplastic Syndrome. *Blood* 130(Suppl 1):4265, 12/2017.
 88. Christopher Peter Mill, Warren Fiskus, DiNardo CD, Yimin Qian, Kanak Raina, Takahashi K, Kadia T, Dyana T. Saenz, Agnieszka J Nowak, Baohua Sun, Craig M Crews and Kapil N. Bhalla. Targeted Therapy for AML Expressing RUNX1 Mutation. *Blood* 130(Suppl 1):2472, 12/2017.
 89. Maiti A, Kantarjian HM, Vinita Popat, Garcia-Manero G, Konopleva M, Verstovsek S, Andreeff M, Borthakur G, Tapan Kadia, Naval Daver, Pemmaraju N, DiNardo CD, SherryPierce, William G Wierda, Steven Kornblau, Ravandi F, Cortes JE. The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right? *Blood* 130(Suppl 1):4693, 12/2017.
 90. Swaminathan M, Kantarjian HM, Daver N, Borthakur G, Ohanian M, Kadia T, DiNardo CD, Jain N, Estrov Z, Ferrajoli A, Garcia-Manero G, Konopleva M, Andreeff M, Pemmaraju N, Jabbour EJ, Wierda WG, Ravandi F, Pinsoy MR and Cortes JE. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. *Blood* 130(Suppl 1):723, 12/2017.
 91. Assi R, Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau S, Kadia T, Daver N, Brandt M, Pierce S, Huang X, Garcia-Manero G, Kantarjian HM and Ravandi F. The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial. *Blood* 130(Suppl 1):1379, 12/2017.
 92. Yilmaz M, Devendra KC, Mary Abisola Akosile, Joseph David Khoury, Short NJ, Cortes JE, Garcia-Manero G, Ravandi F, Kadia T, Sasaki K, Konopleva M, Wierda WG, NitinJain, Verstovsek S, Estrov Z, Pierce S, O'Brien SM, Jabbour EJ and Kantarjian HM. The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL). *Blood* 130(Suppl 1):2712, 12/2017.
 93. Assi R, Kantarjian HM, Rita Khouri, Ravandi F, Partow Kebriaei, Short NJ, Deborah A Thomas, Garcia-Manero G, Richard E Champlin, Kadia T, Cortes JE, Jain N, Konopleva M, ZeevEstrov, Takahashi K, Sasaki K, Jovitta Jacob, Ameena Manzoor, Garris R, O'Brien SM and Jabbour EJ. Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL). *Blood* 130(Suppl 1):2597, 12/2017.
 94. Ghorab A, Patel K, Cortes JE, Dai Chihara, Price A, Kadia TM, Ravandi F, Pemmaraju N, Daver NG, Dinardo CD, Kantarjian HM, Borthakur G;. Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation. *J Clin Oncol* 36(Suppl; abstr 7069), 6/2018.
 95. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Zeev Estrov, Jabbour EJ, Ravandi F-Kashani, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Kapil Bhalla, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib

- in combination with azacitidine in patients with myelofibrosis. *Blood* 132(Suppl 1):1664-1674, 12/2018.
96. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, YesidAlvarado, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, KiranNaqvi, Cortes JE, Kadia TM, Konopleva MY, Simona Colla, Hui Yang, Caitlin R. Rausch, YvonneGasior, Carlos E. Bueso-Ramos, Kanagal-Shamanna R, Patel KP, Kantarjian HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). *Blood* 132(Suppl 1):465, 12/2018.
 97. Jain N, Ferrajoli A, Sreyashi Basu, Philip A. Thompson, Burger JA, Kadia TM, Estrov ZE, Pemmaraju N, Wanda Lopez, Beenu Thakral, Joseph David Khoury, Carlos E. Bueso-Ramos, Jorge Blando, O'Brien SM, Kantarjian HM, James P Allison, Keating MJ, Sharma P, Wierda WG. A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation. *Blood* 132(Suppl 1):296, 12/2018.
 98. Assi R, Boddu P, Kadia TM, Estrov ZE, Garcia-Manero G, Ravandi F, Jabbour EJ, Takahashi K, Konopleva MY, Andreeff M, Abdallah Abou Zahr, DiNardo CD, Borthakur G, Jain N, Pemmaraju N, Yilmaz ME, Short NJ, Jing Ning, Pierce SA, Wierda WG, Cortes JE, Kantarjian HM, Daver NG. Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts. *Blood* 132(Suppl 1):3689, 12/2018.
 99. Short NJ, Jabbour EJ, Ravandi F, Huang X, Jain N, Sasaki K, Pemmaraju N, Daver NG, Joseph David Khoury, Jorgensen JL, Alvarado Y, Konopleva MY, Garcia-Manero G, Kadia TM, Yilmaz M, Borthakur G, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Nasnas P, Jovitta Jacob, Garris RE, O'Brien SM, Kantarjian HM. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. *Blood* 132(Suppl 1):36, 12/2018.
 100. Mansour Alfayez, Kantarjian HM, Ravandi F, Garcia-Manero G, Konopleva MY, Daver NG, DiNardo CD, Borthakur G, Bose P, Andreeff M, Alvarado Y, Yilmaz ME, Pemmaraju N, Kornblau SM, Estrov ZE, Benton CB, Takahashi K, Naqvi K, Slack R, Islam R, Jabbour EJ, Cortes JE, Kadia TM. Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤ 65 yrs) with Acute Myeloid Leukemia. *Blood* 132(Suppl 1), 12/2018.
 101. Swaminathan M, Morita K, Yuanqing Y, Wang F, Burks J, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Zhang J, Song X, DiNardo CD, Jabbour EJ, Kadia TM, Cortes JE, Daver NG, Pemmaraju N, Keyur Patel, Garcia-Manero G, Kantarjian HM, Bueso-Ramos CE, Futreal A, Takahashi K. Clinical Heterogeneity of AML Is Associated with Mutational Heterogeneity. *Blood* 132(Suppl 1):5240, 12/2018.
 102. Jain N, Keating MJ, Philip A. Thompson, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Zeev E. Estrov, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian MN, Pemmaraju N, Jabbour EJ, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). *Blood* 132(Suppl 1), 12/2018.
 103. Feng Wang, Kiyomi Morita, DiNardo CD, Keyur Patel, Kyle MacBeth, Alessandra Tosolini, Mark G. Frattini, Jairo Matthews, Latasha Little, Curtis Gumbs, Samantha Tippen, Xingzhi Song, Jianhua Zhang, Erika Thompson, Kadia TM, Garcia-Manero G, Jabbour EJ, Ravandi F, Konopleva MY, Kantarjian HM, Futreal A, Takahashi K. Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance. *Blood* 132(Suppl 1):441, 12/2018.
 104. Tallis E, Benton CB, Khan A, Assi R, DiNardo CD, Hornbaker MJ, Catherine Kendall Major, Prajwal Boddu, Kanagal-Shamanna R, Keyur P. Patel, Daver NG, Takahashi K, Montalban-Bravo G, Kadia TM, Konopleva MY, Andreeff M, Kantarjian HM, Garcia-Manero G. Diverse Landscape of TET2 Variants in MDS and AML. *Blood* 132(Suppl 1), 12/2018.
 105. Garcia-Manero G, Montalban-Bravo G, Sasaki K, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM,

- Konopleva MY, Rausch CR, Gasior Y, Kantarjian HM. Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). *Blood* 132(Suppl 1):1831, 12/2018.
106. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Alvarez J, Khouri M, Nasnas P, Garris RE, Wierda WG, Thompson PA, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood* 132(Suppl 1):2695, 12/2018.
 107. Masarova L, Daver NG, Kadia TM, Pemmaraju N, Jabbour EJ, Lingsha Zhou, Pierce SA, Cortes JE, Kantarjian HM, Verstovsek S. Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia — Final Results of a Prospective Phase 2 Study. *Blood* 132(Suppl 1):1764, 12/2018.
 108. Swaminathan M, Kantarjian HM, Sasaki K, Ravandi F, Borthakur G, Kadia TM, Garcia-Manero G, DiNardo CD, Konopleva MY, Estrov ZE, Pemmaraju N, Daver NG, Wierda WG, Ferrajoli A, Pierce SA, Dellasala MDE, Jabbour EJ, Cortes JE. Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. *Blood* 132(Suppl 1):3013, 12/2018.
 109. Kanagal-Shamanna R, Sasaki K, Guillermo Montalban Bravo, Benton CB, Jabbour EJ, Borthakur G, Kadia TM, Carlos E. Bueso-Ramos, Keyur Patel, Ravandi F, Kantarjian HM, Garcia-Manero G. Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. *Blood* 132(Suppl 1):1820, 12/2018.
 110. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Kristy R. Bodden, Bose P, YesidAlvarado, Daver NG, Borthakur G, Ravandi F, Takahashi K, Cortes JE, Jabbour EJ, Naqvi K, DiNardo CD, Benton CB, Pemmaraju N, Kadia TM, Ohanian MN, Pierce SA, Kantarjian HM. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). *Blood* 132(Suppl 1):232, 12/2018.
 111. Daver NG, Assi R, Kantarjian HM, Cortes JE, Ravandi F, Konopleva MY, Tapan M.Kadia, Borthakur G, Jabbour EJ, DiNardo CD, Michelle Velasquez, Mary Kelly, Jing Ning, Graciela M. Noguera González, Pierce SA, Dan Gombos, Estrov ZE, Kornblau SM, Weiguo Zhang, Andreeff M. Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML). *Blood* 132(Suppl 1):1441, 12/2018.
 112. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian MN, DiNardo CD, Estrov ZE, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce SA, Cortes JE, Konopleva MY, Garcia-Manero G, Ravandi F. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. *Blood* 132(Suppl 1):84, 12/2018.
 113. Roman D, Kantarjian HM, Cortes JE, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Daver NG, Pemmaraju N, Kadia TM, Kornblau SM, Bose P, Andreeff M, Freireich EJ, Ravandi F, Aung FM. Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. *Blood* 132(Suppl 1):2544, 12/2018.
 114. Jain N, Philip A. Thompson, Burger JA, Ferrajoli A, Borthakur G, Bose P, Zeev E. Estrov, Kadia TM, Takahashi K, Naveen Garg, Xuemei Wang, Kanagal-Shamanna R, Keyur Patel, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. *Blood* 132(Suppl 1):695, 12/2018.
 115. Sasaki K, Kantarjian HM, Short NJ, Ravandi F, Maria Khouri, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Ghayas C. Issa, Jovitta Jacob, Garris RE, Yilmaz M, Thompson PA, Nasnas P, Pemmaraju N, Cortes JE, O'Brien SM, Jabbour EJ. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. *Blood* 132(Suppl 1):34, 12/2018.

116. Abhishek Maiti, DiNardo CD, Cortes JE, Borthakur G, Pemmaraju N, Christopher B. Benton, Kadia TM, Takahashi K, Naqvi K, Ravandi F, Alvarado Y, Short NJ, Daver NG, Sasaki K, Ohanian MN, Garcia-Manero G, Philip A. Thompson, Kornblau SM, Lucia Masarova, Jain N, Jabbour EJ, Andreeff M, Rita Maduiké, Julio A Guerrero, Qi Zhang, Cavazos, A, Helen Ma, Caitlin R. Rausch, Carol A. Bivins, Vaughan K, Pierce SA, Jing Ning, Wei Qiao, John S. Welch, Kantarjian HM, Konopleva MY. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood* 132(Suppl 1):286, 12/2018.
117. Bose P, McCue D, Wiederhold NP, Kadia TM, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Philip A. Thompson, Pemmaraju N, Daver NG, Burger JA, Cortes JE, Garcia-Manero G, Verstovsek S, Konopleva MY, Jain N, DiNardo CD, Alvarado Y, Naqvi K, Kornblau SM, Ferrajoli A, Wierda WG, Zeev E. Estrov, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. *Blood* 132(Suppl 1), 12/2018.
118. Montalban-Bravo G, Benton CB, Kanagal-Shamanna R, Sasaki K, Assi R, Kadia TM, Ravandi F, Ganan-Gomez I, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Pemmaraju N, Konopleva MY, Pierce SA, Bueso-Ramos CE, Kornblau SM, Patel K, Colla S, Kantarjian HM, Andreeff M, Garcia-Manero G. Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Blood* 132(suppl 1):2791, 12/2018.
119. Pemmaraju N, Bing Z Carter, Kantarjian HM, Cortes JE, Kadia TM, Garcia-Manero G, DiNardo CD, Bose P, Daver NG, Konopleva MY, Ohanian MN, Pierce SA, Lingsha Zhou, Estrov ZE, Borthakur G, Karina Salinas, Po Yee Mak, Jain N, Jabbour EJ, Verstovsek S. LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. *Blood* 132(Suppl 1):687, 12/2018.
120. Christopher Peter Mill, Tianyu Cai, Warren Fiskus, Borthakur G, Kornblau SM, Kadia TM, DiNardo CD, Agnieszka J Nowak, Dyana T. Saenz, David N Saenz, Baohua Sun, Thurika Ganesh, Wendy Jin, Vaishnavi Rao, Joseph David Khoury, Yu Shen, Konopleva MY and Kapil N. Bhalla. Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells. *Blood* 132(Suppl 1):1351, 12/2018.
121. Montalban Bravo G, Kanagal-Shamanna R, Benton CB, Simona Colla, Irene Ganan-Gomez, Sasaki K, Ravandi F, Kadia TM, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Naqvi K, Konopleva MY, Pierce SA, Carlos E. Bueso-Ramos, Keyur Patel, Kantarjian HM, Garcia-Manero G. Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. *Blood* 132(Suppl 1):1514, 12/2018.
122. Bannon S, Routbort M, Garcia-Manero G, Daver NG, Oran B, Borthakur G, Mehta RS, Naqvi K, Takahashi K, Alvarado Y, Kadia TM, Kantarjian HM, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. *Blood* 132(Suppl 1):2667, 12/2018.
123. Dyana T. Saenz, Warren Fiskus, Taghi Manshoury, David N Saenz, Raffaella Soldi, Baohua Sun, Christopher Peter Mill, Agnieszka J Nowak, Kornblau SM, Bose P, Kadia TM, DiNardo CD, Lucia Masarova, Steve Horrigan, Joseph David Khoury, Sunil Sharma, Verstovsek S and Kapil N. Bhalla. Novel BET Protein Degradation-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β -Catenin-TCF7L2-MYC Axis. *Blood* 132(Suppl 1):177, 12/2018.
124. Tallis E, Kantarjian HM, Major CK, Vazquez M, Borthakur G, Bose P, Ravandi F, Garcia-Manero G, Kadia TM, Wierda WG, Ferrajoli A, Pemmaraju N, Daver NG, DiNardo CD, Konopleva MY, Kornblau SM, Champlin RE, Jabbour EJ, Pierce SA, Cortes JE. Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKI. *Blood* 132(Suppl 1):2702, 12/2018.
125. Alfayez M, Kantarjian HM, Ravandi F, Konopleva MY, Garcia-Manero G, Tapan M. Kadia, Jabbour EJ, Borthakur G, DiNardo CD, Estrov ZE, Pemmaraju N, Pierce SA, Yilmaz ME,

- Short NJ, Takahashi K, Assi. Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. *Blood* 132(Suppl 1):663, 12/2018.
126. Kiyomi Morita, Feng Wang, Hideki Makishima, Yuanqing Yan, Tetsuichi Yoshizato, Kenichi Yoshida, Bartłomiej P. Przychodzen, Keyur Patel, Carlos E. Bueso-Ramos, Curtis Gumbs, Latasha Little, Samantha Tippen, Jianhua Zhang, Xingzhi Song, Kadia TM, Daver NG, Pemmaraju N, DiNardo CD, Ravandi F, SrdanVerstovsek, Jabbour EJ, Cortes JE, Kantarjian HM, Garcia-Manero G, Jaroslaw P. Maciejewski, Seishi Ogawa, P Andrew Futreal, Takahashi K. Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data. *Blood* 132(Suppl 1):1801, 12/2018.
 127. Rausch CR, Paul S, Montalban Bravo G, Jabbour EJ, Daver NG, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Kornblau SM, Cortes JE, Kadia TM, Konopleva MY, Ohanian MN, Pierce SA, Gasior Y, Benton CB, Jain N, Takahashi K, Masarova L, Andreeff M, Estrov ZE, Kantarjian HM, Garcia-Manero G. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. *Blood* 132(Suppl 1), 12/2018.
 128. Aboudalle I, Kantarjian HM, Ravandi F, Jabbour EJ, Daver NG, Estrov ZE, MichaelAndreeff, Ferrajoli A, DiNardo CD, Pemmaraju N, Naqvi K, Jain N, Sarah GwenPelletier, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission. *Blood* 132(Suppl 1):2714, 12/2018.
 129. Masarova L, Cortes JE, Patel KP, O'Brien SM, Noguera González GM, Konopleva MY, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi F, Borthakur G, Dellasala SE, Jabbour EJ, Kantarjian HM. Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up. *Blood* 132(Suppl 1):3011, 12/2018.
 130. Kadia TM, Konopleva MY, Garcia-Manero G, Benton CB, Wierda WG, Bose P, Yilmaz ME, Jabbour EJ, Kornblau SM, Kapil N. Bhalla, Pemmaraju N, Jain N, Rashmi Malla, Borthakur G, Cortes JE, Ravandi F, Kantarjian HM. Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. *Blood* 132(Suppl 1):4057, 12/2018.
 131. Aboudalle I, Kantarjian HM, Ohanian MN, Alvarado Y, Jabbour EJ, Garcia-Manero G, Naqvi K, Wierda WG, Daver NG, Burger JA, Konopleva MY, Takahashi K, Andreeff M, Pemmaraju N, Ferrajoli A, Borthakur G, Kadia TM, Ravandi F, Cortes JE. Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. *Blood* 132(Suppl 1):2715, 12/2018.
 132. Alfayez M, Kantarjian HM, Kadia TM, Garcia-Manero G, Ravandi F, Borthakur G, DiNardo CD, Rios MB, Jabbour EJ, Cortes JE. Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience. *Blood* 132(Suppl 1):5447, 12/2018.
 133. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Kadia TM, Cortes JE, Alousi AM, Konopleva MY, DiNardo CD, Rezvani K, Alfayez M, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver NG. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. *Blood* 132(Suppl 1), 12/2018.
 134. Yalniz F, Kantarjian HM, Borthakur G, Kadia TM, Daver NG, Pemmaraju N, Konopleva MY, Garcia-Manero G, Takahashi K, DiNardo CD, Bose P, Andreeff M, Ravandi F, Cortes JE. Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia. *Blood* 132(Suppl 1):3996, 12/2018.
 135. Aboudalle I, Kantarjian HM, Short NJ, Konopleva MY, Jain N, Garcia-Manero G, Garris RE, Qiao W, Cortes JE, O'Brien SM, Kebriaei P, Kadia TM, Jabbour EJ, Ravandi F. Predictors of Outcomes in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors. *Blood* 132(Suppl 1):2659, 12/2018.
 136. Yalniz F, Kantarjian HM, Kadia TM, Garcia-Manero G, Keyur Patel, Sanam Loghavi, KojiSasaki, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K,

- Pierce SA, Cortes JE, Ravandi F. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. *Blood* 132(Suppl 1):3983, 12/2018.
137. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. *Blood* 132(Suppl 1) (#4971), 12/2018.
 138. Assi R, Kantarjian HM, Daver NG, Garcia-Manero G, Benton CB, Philip A. Thompson, Borthakur G, Kadia TM, Alvarado Y, Jabbour EJ, Konopleva MY, Takahashi K, Kornblau SM, DiNardo CD, Estrov ZE, Wilmer Flores, Sreyashi Basu, James P Allison, Padmanee Sharma, Pierce SA, Allison Pike, Cortes JE, Ravandi F. Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). *Blood* 132(Suppl 1):905, 12/2018.
 139. Swaminathan M, Stavrou N, Antzoulatos S, Albitar M, Patel K, Cortes JE, DiNardo CD, Kadia TM, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Borthakur G. RNA Expression Profile Using Targeted NGS As a Potential Predictor of Early Molecular Response and Relapse in Core-Binding Factor Acute Myeloid Leukemia. *Blood* 132(Suppl 1):5113, 12/2018.
 140. Alfayez M, Kantarjian HM, Nicholas J Short, Assi R, Khouri M, Ravandi F, Paul S, Rausch CR, Nasnas P, Borthakur G, DiNardo CD, Kadia TM, Daver NG, Garcia-Manero G, Naqvi K, Bose P, O'Brien SM, Cortes JE, Jabbour EJ. Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. *Blood* 132(Suppl 1):2702, 12/2018.
 141. Rampal RK, Verstovsek S, Devlin SM, Stein EM, Kadia TM, Mauro MJ, Pemmaraju N, Alvarez K, Ard N, Goodman T, Marek K, Bose P. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial results of a Phase II Study. *Blood* 132(Suppl 1):354 (#114125), 12/2018.
 142. Daver NG, Garcia-Manero G, Sreyashi Basu, Cortes JE, Ravandi F, Kadia TM, Konopleva MY, Jabbour EJ, DiNardo CD, Assi R, Pierce SA, Alvarado Y, Estrov ZE, Pemmaraju N, Takahashi K, Jing Ning, Graciela M. Nogueras González, Kornblau SM, MansourAlfayez, Jairo Matthews, Wilmer Flores, Jorge Blando, James P Allison, Padmanee Sharma, Kantarjian HM. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. *Blood* 132(Suppl 1):906, 12/2018.
 143. Ravandi F, Pierce SA, Garcia-Manero G, Kadia TM, Jabbour EJ, Borthakur G, DiNardo CD, Daver NG, Short NJ, Alvarado Y, Cortes JE, Kim C, AKelsh M, Katz AJ, Williams R, Yang Z, Mehta B, Kantarjian HM. Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. *Blood* 132(Suppl 1):3985, 12/2018.
 144. Sasaki K, Kantarjian HM, Ravandi F, Short NJ, Partow Kebriaei, Xuelin Huang, Michael E. Rytting, Jain N, Konopleva MY, Garcia-Manero G, Richard E Champlin, Kadia TM, Jorge E. Cortes, Estrov ZE, Takahashi K, Morgan Mace, Maria Khouri, Patrice Nasnas, Jovitta Jacob, Rebecca E. Garris, Jabbour EJ. Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. *Blood* 132(Suppl 1):553, 12/2018.
 145. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Ghayas C. Issa, Estrov ZE, Garris RE, Khouri M, Nasnas P, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). *Blood* 132(Suppl 1):2664, 12/2018.
 146. Major CK, Kantarjian HM, Borthakur G, Kadia TM, Pemmaraju N, Nicholas J Short, Daver NG, Jabbour EJ, Richard E Champlin, Garcia-Manero G, Konopleva MY, Andreeff M, Kornblau SM, Wierda WG, Pierce SA, Ravandi F, Cortes JE. Survivorship in AML -

- Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs). *Blood* 132(Suppl 1):3976, 12/2018.
147. Fiskus W, Mill CP, Soldi R, Han R, Saenz DT, Nowak AJ, Sun B, Saenz DN, DiNardo CD, Borthakur G, Kadia TM, Jin W, Ganesh T, Rao V, Khoury JD, Sharma S, Bhalla KN. Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells. *Blood* 132(Suppl 1):3930, 12/2018.
 148. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Naqvi K, Pierola AA, Yilmaz M, Short NJ, Jabbour EJ, Ravandi F, Kadia TM, Pierce SA, Takahashi K, DiNardo CD, Nogueras González GM, Abaza Y, Devendra KC, Chamoun K, Sakurai K, Patel KP, Cortes JE, Kantarjian HM, Garcia-Manero G. The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood* 132(Suppl 1):4359, 12/2018.
 149. DiNardo CD, Albitar M, Kadia TM, Naqvi K, Vaughan K, Cavazos, A, Pierce SA, Takahashi K, Kornblau SM, Ravandi F, Cortes JE, Kantarjian HM, Konopleva MY. Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study. *Blood* 132(Suppl 1), 12/2018.
 150. Chamoun K, Kantarjian HM, Naqvi K, Wang X, Garcia-Manero G, Borthakur G, Jabbour EJ, Kadia TM, Daver NG, DiNardo CD, Jain N, Konopleva MY, Jorge E. Cortes, Ravandi F, Yilmaz M. Weight Increase during Induction Therapy Predicts Intensive Care Unit (ICU) Transfer in Patients (Pts) with Acute Promyelocytic Leukemia (APL). *Blood* 132(Suppl 1), 12/2018.

Book Chapters

1. Tapan Kadia, Farhad Ravandi. Induction Therapy in Acute Myeloid Leukemia. In: *Cancer: Expert Clinical Perspective*, 2014.
2. Kainthala, R. Pemmaraju, N. Kadia T. Leukemias. In: *Handbook of Targeted Therapy.*, 2014.
3. Tapan Kadia, Joseph Khoury, Farhad Ravandi. Acute Myeloid Leukemia. In: *MD Anderson Manual of Medical Oncology* 2021

Books (edited and written)

N/A

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Editorial Review Board Member, *ACTA Haematologica*, 2017-present

Associate Editor, *Hematology*, 2019-2020

Member of Editorial Review Board

Editorial Review Board Member, *Clinical Lymphoma Myeloma and Leukemia*, 2017-present

Journal Reviewer

ad hoc Reviewer, *Cancer*, 2009-present

ad hoc Reviewer, *Haematologica*, 2010-present

ad hoc Reviewer, *Leukemia and Lymphoma*, 2011-present

ad hoc Reviewer, *British Journal Of Haematology*, 2012-present

ad hoc Reviewer, *Blood*, 2014-present

ad hoc Reviewer, *Blood Journal*, 2014-present

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

Lecturer and Member of Steering Committee, M D Anderson, Baylor College of Medicine
Hematology and Oncology Board Review Course
1/2014-present

Training Programs

N/A

Other Formal Teaching

Lecturer, U.T. Internal Medicine Resident formal lectures on Oncologic Emergencies
1/2005-9/2008

Lecturer, Leukemia, MDS, Aplastic Anemia
1/2012-present

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

Fevzi Yalniz

Research and Clinical Mentor, Leukemia Fellowship, MDACC,, Guillaume Richard-Carpentier

Research and Clinical Mentor, MDACC, Hussein Abbas

Research and Clinical Mentor, Leukemia Fellowship, MDACC, Iman Abou Dalle

Research and Clinical Mentor, Leukemia Fellowship, MDACC,, Kunwha Kim

Mahran Shoukier

Mansour Alfaez

Megan Dupuis

Medical Oncology Fellows, Cancer Medicine, The University Of Texas MD Anderson Cancer Center, Multiple trainees

Leukemia Fellows, Department of Leukemia, The University Of Texas MD Anderson Cancer Center, Multiple trainees

Research and Clinical Mentor, MDACC, Patrick Reville

Research and Clinical Mentor, Leukemia Fellowship, MDACC, Prajwal Boddu

Research and Clinical Mentor, Leukemia Fellowship, MDACC, Rita Assi

Roman Darwin

Research and Clinical Mentor, Leukemia Fellowship, MDACC,, Veronica Guerra

Research and Clinical Mentor, Leukemia Fellowship, MDACC, Daniel Rivera

Research and Clinical Mentor, Leukemia Fellowship, MDACC, Sangeeta Venugopal

Research and Clinical Mentor, Leukemia Fellowship, MDACC, Danielle Hammond

Clinical Mentor, Leukemia Fellowship, MDACC, Maria Siddiqui

Other Supervisory Teaching

N/A

Teaching Outside Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

Lecturer, Core Internal Medicine Chief Resident Lecture Series - Students and Residents, Baylor College of Medicine
1/2004-1/2005

Lecturer, Internal Medicine Residents, Oncologic Emergencies, UT Medical School

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

University of Texas Health Science Center, Kelly Casteel, MD, Internal Medicine Residents

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

N/A

Presentations at National or International Conferences

Invited

What's new in CML from American Society of Hematology (ASH) Meeting?, American Society of Hematology, Orlando, FL, 1/23/2010

Management of AML after MDS in non - transplant candidates, Congress of the Columbian Association of Hematology & Oncology, Armenia, Bogota, Colombia, 11/12/2010

Supportive therapy in MDS, Congress of the Columbian Association of Hematology & Oncology, Armenia, Bogota, Colombia, 11/12/2010

Advances in MDS Treatment: What's on the Horizon, Aplastic Anemia & MDS International Foundation, Dallas, TX, 9/22/2012

MDS: Current Thinking of the Disease, Diagnosis and Treatment (Lower-Risk), Aplastic Anemia & MDS International Foundation, Dallas, TX, 9/22/2012

New Therapy Options for Management of AML Patients, 4th Annual Regional Hematology – Oncology Symposium, Cartagena, Colombia, 5/18/2013

Treatment Sequence for AML Patients, 4th Annual Regional Hematology – Oncology Symposium, Cartagena, Colombia, 5/18/2013

Drug of Choice for Chronic Myelogenous Leukemia?, Asia Pacific Hematology Consortium AUBH2013, Bangkok, Thailand, 8/30/2013

High Risk MDS: Upfront Transplant?, Asia Pacific Hematology Consortium AUBH2013, Bangkok, Thailand, 8/30/2013

Is 7+3 still the induction regimen for Acute Myeloid Leukemia patients?, Asia Pacific Hematology Consortium AUBH2013, Bangkok, Thailand, 8/30/2013

Malignant Hematology - Case and Topic Review, 2013 Comprehensive Board Review in Hematology and Medical Oncology, Houston, TX, 9/25/2013

ASH Update in Chronic Myeloid Leukemia, ASH, Orlando, FL, 1/25/2014

Update on Hematologic Malignancies for The Primary Care Physician, Texas Academy of Family Physicians 65th Annual Session, San Antonio, TX, 7/26/2014

Medical Oncology and Hematology 2014 Meeting, Advances and Treatment of MDS, Houston, TX, 10/16/2014

Hypomethylating Agents in AML: Past, Present, and Future, Spanish Society of Hematology and Therapy, Madrid, Spain, 9/30/2016

Kadia T. Cladribine in AML, 8th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy, Jekyll Island, GA, 1/14/2017

Session Chair: Leukemia, MDS, Allogeneic SCT, American Society of Clinical Oncology (ASCO), Chicago, IL, 6/6/2017

Acute Myeloid Leukemia in the WHO 2016 Classification: What is going to change? What will be the therapeutic impact?, The Albert Einstein Research and Education Institute --XI Board Review in Hematology and Transfusion Medicine, Sao Paulo, Brazil, 6/29/2017

Treatment of Myelodysplastic Syndromes, The Albert Einstein Research and Education Institute - XI Board Review in Hematology and Transfusion Medicine, Sao Paulo, Brazil, 6/30/2017

New Frontiers in the Management of Acute Myeloid Leukemia (AML): Exploring Emerging Treatment Options, NAMCP - National Association of Managed Care Physicians, Las Vegas, NV, 10/27/2017

Treatment of Older Patients with AML, EBMT Annual Meeting, Lisbon, Portugal, 3/18/2018

Novel Agents in AML, EBMT Annual Meeting, Lisbon, Portugal, 3/19/2018

Kadia t. Treating Patients with Acute Myeloid Leukemia, Hikma Cancer Network, 2nd Annual MENA Cancer Conference, Dead Sea, Jordan, Jordan, 4/9/2018

Clinical Plenary Session Discussant: Phase III ADMIRAL Trial of Gilteritinib in R/R AML, American Association of Cancer Research (AACR), Atlanta, GA, 4/2/2019

Management of Lower Risk MDS, Hikma Cancer Network, Annual MENA Conference, Lisbon, Portugal, 4/11/2019

Leveraging Evidence to Optimize Applications of Novel Therapies in AML - Personalizing Therapy in AML, Satellite Education Session, American Society of Clinical Oncology (ASCO), Chicago, IL, 5/31/2019

EDUCATION SESSION: Less is More in the Treatment of Older Patients with AML, American Society of Clinical Oncology (ASCO), Chicago, IL, 6/2019

MDACC Experience of T-Prolymphocytic Leukemia, Postponed, International T-PLL Consortium Meeting, Vienna, Austria, 5/7/2020

Kadia, Tapan. Treating Older Patients with Newly Diagnosed AML, 2nd Italian Conference, Italian Society of Hematologic Oncology SOHO, Rome, Italy, 9/22/2020

Kadia, Tapan. Treating Older Patients with Newly Diagnosed AML, Proeventi, SOHO 2nd Italian Conference, Rome, 9/22/2020

Other, Including Scientific Exhibitions

Acute Myeloid Leukemia – Biology And Pathophysiology: Biologic and Clinical Correlative Studies, American Society of Hematology, New Orleans, LA, 12/7/2009

Malignant Hematology - Case and Topic Review, MDACC, Houston, TX, 9/2010

Malignant Hematology - Question and Case Review, MDACC, Houston, TX, 9/2011

Malignant Hematology - Question and Case Review, MDACC, Houston, TX, 9/2012

Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML), American Society of Hematology, San Francisco, CA, 12/8/2014

Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia, American Society of Hematology, Orlando, FL, 12/4/2015

Outcomes with Lower Intensity Therapy in TP53-Mutated Acute Myeloid Leukemia (AML), American Society of Clinical Oncology (ASCO), Chicago, IL, 6/2/2017

Lenalidomide Maintenance in Patients with High Risk Acute Myeloid Leukemia, EHA - 22nd Congress of the European Hematology Association, Madrid, Spain, 6/23/2017

Understanding Risk in MDS, "The Good, the Bad, and the Ugly," Society of Hematologic Oncology (SOHO), Houston, TX, 9/13/2017

Treating AYA ALL - The Adult Leukemia Experience, 2nd Annual Global AYA Congress, Atlanta, GA, 12/5/2017

3+7 is No Longer the Standard of Care, Hikma Cancer Network, 2nd Annual MENA Cancer Conference, Dead Sea, Jordan, 4/9/2018

Novel Agents in AML, Hikma Cancer Network, 2nd Annual MENA Cancer Conference, Dead Sea, Jordan, 4/9/2018

Kadia T. Nivolumab Maintenance in high-risk Acute Myeloid Leukemia (AML) Patients, American Society of Clinical Oncology (ASCO), Chicago, IL, 6/2/2018

Kadia T. Phase IB Study of the CXCR4 antagonist BL8040 combined with immunosuppressive Therapy in patients with Aplastic Anemia, European Hematology Association (EHA), Stockholm, SE, Sweden, 6/18/2018

Management of Older Patients with Newly Diagnosed AML, Hikma Cancer Network, Annual MENA Conference, Lisbon, Portugal, 4/11/2019

AML in Older Patients: Something is Changing, Society of Hematologic Oncology - Columbia, Bogota, Colombia, 4/26/2019

State of the Art in AML, Society of Hematologic Oncology - Columbia, Bogota, Colombia, 4/26/2019

What's the Place of New Agents in AML?, Society of Hematologic Oncology - Columbia, Bogota, Colombia, 4/26/2019

Approach To the Treatment of Older Patients with AML, Italian Society of Hematologic Oncology (SOHO), Rome, Italy, 9/25/2019

How I Treat Elderly AML, Italian Society of Hematologic Oncology, Rome, Italy, 9/25/2019

Tapan Kadia. Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML), ASH, 12/5/2020

Tapan Kadia. Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML), ASH, 12/5/2020

New Biological Insights ad Novel Drugs in AML, Section of Hematology & Romagna Metropolitan Transplant Network - Hospital of Ravenna, Ravenna, Italy, 5/14/2021

Seminar Invitations from Other Institutions

State of the Art in the Treatment of AML, Baylor College of Medicine, Houston, TX, 1/4/2015

Updates and Review in Leukemia from the American Society of Hematology Symposium, Stephenson Cancer Center, The University of Oklahoma, Oklahoma City, OK, 3/14/2015

Management of AYA Acute Lymphoblastic Leukemia, UT San Antonio Health Science Center, San Antonio, TX, 3/3/2017

Personalizing Therapy: New and Emerging Therapeutic Agents in the Treatment of AML, Michigan State University, East Lansing, MI, 5/1/2020

Lectureships and Visiting Professorships

N/A

Other Presentations at State and Local Conferences

Chronic Lymphocytic Leukemia, 2014 Challenging Cases in Hematology, CME, Las Vegas, NV, 4/26/2014

Chronic Myelogenous Leukemia, 2014 Challenging Cases in Hematology, CME, Las Vegas, NV, 4/26/2014

Kadia, T. Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts, SOHO 2014, Houston, TX, 9/18/2014

Advances and Treatment of Myelodysplastic Syndrome(MDS), MD Anderson Cancer Center, Houston, TX, 10/16/2014

Challenging Cases in Hematology - CML and CLL, CME, 10/18/2014

Kadia T. New Frontiers in the Management of Acute Myeloid Leukemia (AML): Exploring Emerging Treatment Options, NAMCP Fall Forum, Las Vegas, NV, 10/26/2017

Kadia T. Leukemia in 2018 and Beyond, JAZZ, New York, NY, 8/11/2018

How Can Pathologic Assessment Be Optimized for Patients with AML? Personalizing Therapy in AML, Naples Hematopathology Meeting, Naples, FL, 1/22/2020

ASCO Direct Highlights in Leukemia, American Society of Clinical Oncology (ASCO), Boston, MA, 6/27/2020

ASCO Direct Highlights in Leukemia, American Society of Clinical Oncology (ASCO), Denver, CO, 7/18/2020

ASCO Direct Highlights in Leukemia, American Society of Clinical Oncology (ASCO), San Juan, Puerto Rico, 8/7/2020

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Society of Clinical Oncology (ASCO)
Member, 1/2000-present

American Society of Hematology (ASH)
Member, 1/2000-present

Society of Hematologic Oncology, Houston, TX
Member, 10/2012-present

American Association of Cancer Research (AACR)
Member, 1/2013-present

Local/State

N/A

UNIQUE ACTIVITIES

N/A

DATE OF LAST CV UPDATE

03-11-2021